1. Zero-dimensional 2. Biomaterials 3. Inductive properties 4. Nanomaterials 5. Electronic conductance 6. Magnetic responsiveness 7. Bioelectronics 8. Spintronics 9. Piezoelectricity 10. Ferromagnetic behavior 11. Supramolecular assemblies 12. Artificial atoms (quantum dots) 13. Energy transfer 14. Biofuel cells 15. Sensors 16. Actuation 17. Biomedical applications 18. Functionalized polymers 19. Nanostructures 20. Bioresponsive materials
1. 1000 Genomes Project 2. Genetic sequence variation 3. Rare variants 4. Larger penetrance effects 5. Common variants 6. Human genetics 7. Genome-wide association studies (GWAS) 8. Functional genomics 9. Population genetics 10. Variant classification 11. Sequence analysis 12. mendelian inheritance 13. Functional impact assessment 14. Variant effect prediction 15. Population diversity 16. Statistical significance 17. Genetic counseling 18. Personalized medicine 19. Epigenetics 20. Genetic disease research
1. Abnormal PRP positivity 2. UK population 3. Year 2000 4. Preimplantation genetic testing (PGT) 5. PRP (Platelet-rich plasma) 6. Genetic disorders 7. Congenital conditions 8. Embryonic testing 9. Fetal screening 10. UK healthcare system 11. Neonatal diagnostics 12. Rare mutations 13. Gene analysis 14. Genetic counseling 15. Preconception testing 16. Health surveillance 17. National Health Service (NHS) 18. In vitro fertilization (IVF) 19. Reproductive health 20. Rare disease database 21. Genetic carrier status 22. Antenatal testing 23. UK legislation on genetic testing 24. Preimplantation genetic diagnosis (PGD)
1. Perinatal mortality 2. Low birth weight 3. Fetal growth restriction 4. Neonatal deaths 5. Preterm birth 6. Birth complications 7. Maternal health 8. Infants underweight 9. Neonatal care 10. Antenatal complications 11. Postnatal survival rate 12. Low birth weight babies 13. Congenital anomalies 14. Neonatal mortality rate 15. Maternal nutrition 16. Prenatal care quality 17. Birth outcomes assessment 18. Weight-for-length charts 19. Neonatal intensive care 20. Risk factors for low birth weight.
1. Vitamin B12 deficiency 2. Homocysteine levels 3. Blood chemistry 4. Nutritional imbalance 5. Folic acid interaction 6. Methylation process 7. Niacinamide deficiency 8. Red blood cell production 9. Neural tube defects 10. Anemia 11. Pernicious anemia 12. Defective methionine metabolism 13. Hyperhomocysteinemia 14. Brain health 15. Cardiovascular risks 16. Genetic predisposition 17. Fortified foods 18. Supplements 19. Diagnosis 20. Treatment options.
1. Microerythrocytes 2. High count 3. Severe anemia 4. Homozygous alpha thalassemia 5. Genetic trait 6. Hemoglobin deficiency 7. Oxygen transport 8. Anemia severity 9. Compromised red blood cells 10. Iron deficiency anemia 11. Alpha-thalassemia trait 12. Health risk 13. Cardiovascular complications 14. Blood transfusions 15. Nutritional deficiencies 16. Anemia treatment 17. Genetic counseling 18. Monitoring 19. Regular check-ups 20. Compensatory mechanisms.
1. UK population 2. Asymptomatic carriers 3. Variola jervis (VCJD) 4. Infection 5. Total number 6. COVID-19 (related, as VCJD is a member of the orthopoxvirus family) 7. Public health 8. Prevalence study 9. Surveillance data 10. Testing and screening 11. Risk assessment 12. Non-symptomatic transmission 13. Community spread 14. Virus carrier status 15. Health department reports 16. Epidemiological data 17. COVID-19 immunity 18. COVID-19 vaccination 19. Non-severe disease 20. No symptoms 21. Unexplained illness 22. Control measures 23. Viral exposure 24. Poxviruses 25. Zoonotic transmission 26. Long-term effects 27. Health guidelines 28. Nosocomial transmission 29. Pre-COVID-19 carriers 30. Post-exposure prophylaxis (PEP)
1. Adar1 (adenylate deaminase 1) 2. Dicer (double-stranded RNA binding protein) 3. Pre-microRNA ( pri-miRNA) 4. Cleavage 5. RNA processing 6.剪切 7. RNA interference (RNAi) 8. Small interfering RNA (siRNA) 9. miRNA biogenesis 10.是非编码RNA 11. Adar1-dicer interaction 12. miRNA maturation 13. RNA degradation 14. Gene expression regulation 15. Cellular signaling 16. Transcriptional repression 17. Dicer-mediated cleavage events 18. Non-coding RNA function 19. RNA-RNA interactions 20. DNA methylation regulation.
1. Skin tumors 2. Expression 3. Aire (Abnormal Immune Receptor) 4. Pathology 5. Genetic markers 6. Immunogenicity 7. Tumor biomarkers 8. Autoimmune disorders 9. Leprosy 10. Mycosis fungoides 11. Cutaneous lymphoma 12. HLA class II expression 13. T-cell receptor usage 14. Tumor-infiltrating lymphocytes 15. Cancer genetics 16. Skin cancer genetics 17. Aire-related disorders 18. Environmental factors 19. Innate immune response 20. Genetic testing.
1. Aldh1 expression 2. Breast cancer 3. Prognostic markers 4. Better outcomes 5. Gene expression analysis 6. Survival analysis 7. Metastasis suppression 8. Proliferation control 9. Hormone receptor status 10. Chemoresistance 11. Targeted therapy 12. Genetic correlation 13. Breast cancer subtypes 14. Gene function in cancer 15. Aldehyde dehydrogenase 1 (ALDH1) 16. Breast cancer prognosis 17. Immunohistochemistry 18. Microarray studies 19. Genomic signatures 20. Biomarker validation.
1. Aldh1 expression 2. Breast cancer 3. Prognosis 4. Poorer outcome 5. Genetic marker 6. Metabolic enzyme 7. Aldehyde dehydrogenase 1 (ALDH1) 8. Cancer progression 9. Survival analysis 10. Molecular biomarker 11. Cancer risk 12. Pathological significance 13. Breast cancer subtype 14. Clinicopathological correlation 15. Tumor biology 16. Chemoresistance 17. Therapeutic target 18. Biomarker validation 19. Prognostic biomarker 20. ALDH1-based diagnostics.
1. AMP-activated protein kinase (AMPK) 2. Activation 3. Inflammation 4. Fibrosis 5. Lungs 6. Cellular signaling 7. Metabolic regulation 8. Energy homeostasis 9. Protein synthesis 10. Cell growth 11. Tissue damage 12. Cytokine production 13. Apoptosis 14. Mitochondria 15. Stress response 16. p38 MAPK activation 17. mTOR pathway 18. Extracellular matrix remodeling 19. ROS (reactive oxygen species) 20. Lung injury 21. Chronic obstructive pulmonary disease (COPD) 22. Pulmonary fibrosis therapy 23. Preclinical studies 24. Genetic modifications 25. Environmental triggers.
1. Apoe4 expression 2. iPSC-derived neurons 3. Alpha-beta production 4. Tau phosphorylation 5. GABA neuron degeneration 6. Neurodegeneration 7. Genetic variation 8. Amyloid precursor protein (APP) 9. beta-amyloid (Aβ) 10.tau proteinopathy 11. Alzheimer's disease (AD) 12. Neurotransmitter dysfunction 13. Synaptic impairment 14. Neuroinflammation 15. Cellular stress 16. Mitochondrial dysfunction 17. ApoE4 gene 18. Neuronal toxicity 19. iPSC modeling 20. Cellular biology research.
1. Apoe4 2. Expression 3. IPSC (Induced pluripotent stem cells) 4. Derived neurons 5. Alphabeta production 6. Tau phosphorylation 7. GABA (gamma-aminobutyric acid) neurons 8. Degeneration 9. Neurodegeneration 10. Amyloid beta (Aβ) 11. Tau protein 12. Neuroinflammation 13. Neurological disorders 14. Alzheimer's disease 15. Cellular modeling 16. Neurobiology 17. Protein synthesis 18. Signaling pathways 19. Neuroprotective mechanisms 20. Neurotoxicity.
1. Activation 2. PPM1d 3. Suppression 4. P53 5. Function 6. Molecular regulation 7. DNA binding 8. Transcriptional repression 9. Cell cycle control 10. Tumor suppressor 11. Oncogenic signaling 12. Post-translational modification 13. Phosphorylation 14. Histone modifications 15. Protein-protein interaction 16. Cancer prevention 17. Cellular response 18. Signaling pathway 19. Gene expression 20. DNA damage response (DDR)
1. Activator-Inhibitor Pairing 2. Admpchordin 3. Dorsal Localization 4. Signaling molecules 5. Molecular pair interaction 6. Regulatory mechanism 7. Gene expression control 8. Developmental signaling 9. Neural differentiation 10. Tissue-specific regulation 11. Cell cycle progression 12. Morphogenesis 13. Wnt/β-catenin pathway 14. BMP (bone morphogenetic proteins) 15. Notch signaling 16. Hedgehog (Hh) signaling 17. BMP-chordin complex 18. Admpchordin function 19. Cell surface receptors 20. Extracellular matrix cues.
1. Active H pylori 2. Urease enzyme 3. Polymeric structure 4. Two subunits 5. Urea 6. Ureb 7. Gastric bacteria 8. Infection (H. pylori) 9. Metabolic pathway 10. Urea hydrolysis 11. Urea bond formation 12. Peptide linkages 13. Biochemistry of H. pylori 14. Digestive enzymes 15. Helicobacter pylori infection 16. Ulcerative gastritis 17. Pathogenicity 18. Antagonists or inhibitors 19. Diagnosis (urine or breath tests) 20. Treatment options.
1. Albendazole 2. Lymphatic filariasis 3. Parasitic infection 4. Wuchereria bancrofti 5. Filarial worm disease 6. Intrauterine transmission 7. Mass drug administration (MDA) 8. Microfilariae detection 9. Treatment options 10. Control programs 11. Soil-transmitted helminths 12. Adult worm removal 13. Prevalence mapping 14. Preventive chemotherapy 15. Human lymphatic filariasis (HLF) 16. Drug resistance monitoring 17. Community-based interventions 18. Deworming campaigns 19. Post-treatment follow-up 20. Epidemiological surveillance
1. Alizarin 2. Hydrogen bonding 3. Residues 4. PGAM1 (Protein Gammacatenin 1) 5. Substrate binding 6. Protein interaction 7. Structural biology 8. Molecular dynamics 9. Biochemistry 10. Peptide or amino acids 11. Specificity 12. Catalytic activity 13. Binding pocket 14. pH dependence 15. Altered function 16. Kinase inhibitors 17. Drug targets 18. Structural studies 19. Ligand recognition 20. Protein engineering
1. Hematopoietic stem cells 2. Chromosome segregation 3. Random process 4. Genetic diversity 5. Cell division 6. Homologous chromosome pairing 7. Independent assortment 8. Telomere cohesion 9. Cytokinesis 10. Stem cell differentiation 11. Hematopoiesis 12. T-cell progenitors 13. Myeloid lineage 14. Lymphoid lineage 15. Genetic stability 16. Mitotic recombination 17. Cancer stem cells 18. Normal hematopoiesis 19. Random genetic inheritance 20. Genetic variability in blood development
1. Angiotensin-converting enzyme (ACE) inhibitors 2. Functional renal insufficiency 3. Increased risk 4. Renal dysfunction 5. Chronic kidney disease 6. Hypertension 7. Diabetic nephropathy 8. Cardiac hypertrophy 9. ACE inhibitor-induced nephrotoxicity 10. Renal failure 11. Glomerulopathy 12. Acute kidney injury 13. Electrolyte imbalances 14. Proteinuria 15. Renal concentrating ability 16. GFR (glomerular filtration rate) 17. Chronic kidney disease progression 18. Renal hypoperfusion 19. Hyperkalemia 20. Hyperuremia 21. Renal dosing adjustments 22. ACE inhibitor alternatives 23. Renal surveillance 24. Renal protective measures.
1. Anthrax spores 2. Disposal 3. Easy removal 4. dispersion 5. Containment 6. Decontamination 7. Disinfection 8. Cleanup procedures 9. Sterilization 10. Spore kill agents 11. Hazardous waste management 12. Biological cleanup 13. Disposal methods 14. Disposal facilities 15. Spore reduction techniques 16. Spore elimination 17. Biosecurity measures 18. Disposal regulations 19. Disinfectant products 20. Environmental safety guidelines
1. Antibiotic 2. Gut microbiome 3. Alterations 4. Clostridium difficile 5. Resistance 6. Probiotics 7. Prebiotics 8. Dysbiosis 9. Imbalances 10. Infection 11. Antibiotic-associated diarrhea 12. Clostridioides difficile infection (CDI) 13. Metagenomics 14. Microbial diversity 15. Functional dysbiosis 16. Antimicrobial stewardship 17. Post-antibiotic effect 18. Clostridium difficile toxin 19. Fecal microbiota transplantation 20. Preventive measures.
1. Antiretroviral therapy (ART) 2. Tuberculosis (TB) 3. CD4 cell count 4. Broad range 5. HIV infection 6. HIV-positive individuals 7. Rate reduction 8. Disease prevention 9. HIV/TB co-infection 10. Immune restoration 11. CD4+ T-cell recovery 12. Treatment efficacy 13. High-risk populations 14. Health disparities 15. Chronic immune suppression 16. Tuberculin skin test (TST) 17. Chest X-ray 18. Active TB diagnosis 19. HIV/AIDS management 20. Comprehensive care.
1. Arginine 2. Residue 90 3. P150n (Protein 150, Notch) 4. Interaction 5. EBF1 (ErbB-family member 1) 6. Signaling pathway 7. Notch ligand-receptor binding 8. Membrane association 9. Signal transduction 10. Cell adhesion 11. Developmental biology 12. Epigenetics 13. Tumor suppressor 14. Neurological function 15. Cellular differentiation 16. Protein-protein interaction 17. Co-factor binding 18. Membrane protein engineering 19. Functional importance 20. Mutagenesis studies.
1. Arterioles 2. Lumen diameter 3. Venules 4. Blood vessels 5. Capillary network 6. Blood flow regulation 7. Blood pressure 8. Diameter comparison 9. Respiratory system (for context, in case discussing in relation to blood vessels in the lungs) 10. Nervous system (for context, in case discussing in relation to brain blood vessels) 11. Microcirculation 12. Blood vessel caliber 13. Oxygen transport 14. Circulatory system 15. Blood vessel function 16. Blood vessel walls 17. Venous return 18. Blood vessel anatomy 19. Hypertension (if discussing differences in relation to blood pressure) 20. Diabetic complications (if discussing in relation to impaired blood vessel function in diabetes)
1. Open access publishing 2. Peer-reviewed articles 3. Citation rates 4. Journal articles 5. Traditional publishing models 6. Gold open access (GOA) 7. Green open access (GOA) 8. OA vs. subscription journals 9. Impact factor 10. Citations per article 11. Article visibility 12. Open access databases 13. Bibliometrics 14. Citation analysis 15. Access policies 16. Scholarly impact 17. Article lifecycle 18. Bibliographic databases 19. Journal impact factor controversy 20. Open science principles
1. Open Access publishing 2. Citations rates 3. Article accessibility 4. Scholarly impact 5. Peer-reviewed articles 6. Gold Open Access (GOA) 7. Green Open Access (GOA) 8. Hybrid journals 9. Public domain 10. Digital repositories 11. OA journals vs. traditional print 12. Bibliometrics 13. Citation metrics 14. Journal impact factor (IF) 15. Article visibility 16. Open access policies 17. Open science movement 18. Altmetrics 19. Global Research Identifier (GRID) 20. Open Access Database (OAD)
1. Aspirin 2. Inhibits 3. Production 4. PGE2 5. Cytokine 6. Prostaglandins 7. Anti-inflammatory 8. Acetylsalicylic acid 9. Platelet aggregation 10. Endothelial prostaglandin synthesis 11. Cox pathway 12. Cox-1 inhibition 13. COX-2 suppression 14. Arthritis treatment 15. Pain relief 16. Cardiovascular health 17. Gastrointestinal effects 18. Drug metabolism 19. Biochemistry 20. Anti-proliferative action.
1. Assembly 2. Invadopodia 3. Focal generation 4. Phosphatidylinositol 3,4-bisphosphate (PI3,4-P) 5. Activation 6. Nonreceptor tyrosine kinase (SRC) 7. Signal transduction 8. Membrane protrusion 9. Cell adhesion 10. Cytoskeleton reorganization 11. Integrin-independent motility 12. Extracellular matrix degradation 13. Src family kinases 14. Phosphorylation events 15. Actin polymerization 16. Membrane ruffles 17. Adhesion protein activation 18. Signalosome complex 19. Membrane rafts 20. Cell migration.
1. Asymptomatic 2. Visual impairment 3. Elderly populations 4. Screening 5. Improved vision 6. Preventive care 7. Early detection 8. Vision loss 9. No significant benefit 10. Optometry 11. Comprehensive exams 12. Age-related eye diseases 13. Non-prognostic 14. Statistical significance 15. Population-based studies 16. Vision tests 17. Low awareness 18. Telemedicine 19. Health disparities 20. Vision preservation strategies
1. Auditory Entrainment 2. Visual-Auditory Congruency 3. Cognitive Integration 4. Synchronization 5. Brainwave Frequency Locking 6. Temporal Coupling 7. Audio-Visual Feedback 8. Psychoacoustics 9. Multisensory Learning 10. Perception Enhancement 11. Attentional Focus 12. Auditory Signal Detection 13. Visual-Audio Cues 14. Memory Facilitation 15. Vestibular-Gut Connection 16. Audio-Visual Interference 17. Adaptation to Rhythms 18. Neuroplasticity 19. Binaural Beats 20. Tinnitus Treatment
1. Autologous transplantation 2. Mesenchymal stem cells 3. Opportunistic infections 4. Induction therapy 5. Anti-Interleukin 2 receptor antibodies 6. Cellular immunosuppression 7. Graft-versus-host disease 8. Infection risk 9. Stem cell engraftment 10. Immune modulation 11. Hematopoietic stem cell transplantation 12. Therapeutic intervention 13. Anti-T-cell therapy 14. Post-transplant infection 15. Immune recovery 16. Graft rejection 17. Anti-IL-2 monoclonal antibodies 18. Bone marrow transplantation 19. Organ-specific infections 20. HIV prophylaxis.
1. Autologous transplantation 2. Mesenchymal stem cells (MSCs) 3. Opportunistic infections 4. Induction therapy 5. Anti-interleukin 2 receptor antibodies (anti-IL2R Abs) 6. Cellular immunotherapy 7. Allogenic versus autogenic transplant 8. Graft-versus-host disease (GVHD) prevention 9. Regulatory T cells (Tregs) 10. Immunomodulation 11. Stem cell engraftment 12. Anti-inflammatory effects 13. Reduced risk 14. Infection control in transplantation 15. Stem cell-based immunosuppression 16. Chronic graft failure 17. Antirejection strategies 18. Clinical trials 19. Post-transplant complications 20. Mesenchymal stem cell-derived factors (MSC-DFs)
1. Autologous transplantation 2. Mesenchymal stem cells (MSCs) 3. Lower rejection rates 4. Induction therapy 5. Anti-Interleukin-2 receptor antibodies (anti-IL-2R) 6. Cellular immunosuppression 7. Allogenic versus autogenic transplant 8. Regulatory T-cells 9. Hematopoietic stem cell transplantation (HSCT) 10. Mesenchymal progenitor cells 11. Immune tolerance induction 12. T-cell depletion 13. Reduced graft-versus-host disease (GVHD) 14. Stem cell-based regenerative medicine 15. Clinical trials 16. Anti-rejection drugs 17. Induction protocols 18. Immune modulation 19. Regulatory cytokines 20. Chronic graft failure prevention.
1. Autophagy 2. Aged organisms 3. Senescence 4. Cellular degradation 5. Aging process 6. Protein turnover 7. Intracellular recycling 8. Cellular homeostasis 9.老年病 10. Age-related diseases 11. Stress response 12. Mitochondrial dysfunction 13. Ubiquitin-proteasome system 14. Longevity 15. Cell senescence markers 16. Telomere shortening 17. DNA damage 18. Autophagic flux decline 19. Aging-related disorders 20. Aging biology.
1. Weight loss surgery 2. Bariatric procedures 3. Gastric bypass 4. Sleeve gastrectomy 5. Laparoscopic surgery 6. Metabolic surgery 7. Psychosocial outcomes 8. Mental well-being 9. Depression relief 10. Anxiety reduction 11. Eating disorder recovery 12. Quality of life improvement 13. Cognitive function boost 14. Self-esteem growth 15. Psychological resilience 16. Emotional stability 17. Obesity-related depression 18. Binge eating disorder 19. Body image transformation 20. Mood disorders management
1. Basophils 2. Systemic Lupus Erythematosus (SLE) 3. Disease development 4. Immune response 5. Inflammation 6. Autoimmune disorder 7. Cytokines 8. Eosinophils 9. T-cell activation 10. Antigen-presenting cells (APCs) 11. Immunosuppressive therapy 12. Complement system 13. Activation markers 14. Regulatory T-cells (Tregs) 15. Cytokine balance 16. Immunoregulation 17. Anti-inflammatory drugs 18. Anti-lymphocyte antibodies 19. Lupus nephritis 20. Lupus skin disease (LE)
1. Birth weight 2. Breast cancer 3. Positive association 4. Statistical correlation 5. Neonatal health 6. Maternal nutrition 7. Fetal development 8. Risk factors 9. Infant's weight at birth 10. Birth outcomes 11. Overweight in childhood 12. Adiposity 13. Breast tissue health 14. Epigenetics 15. Environmental influences 16. Preterm birth 17.巨大儿 18. Cancer incidence 19. Maternal obesity 20. Breast cancer screening.
1. TDP-43 2. Respiratory Complex I 3. Proteins (ND3 and ND6) 4. Blocking interaction 5. Neuronal loss 6. Neurodegeneration 7. Protein aggregation 8. Mitochondrial dysfunction 9. ATP synthase 10. Neurological disorders 11. Pathological implications 12. Cellular toxicity 13. Protein misfolding 14. Gain-of-function mechanism 15. Loss-of-function effect 16. Genetic mutations 17. Transient receptor potential channels 18. Neurodegenerative diseases (e.g., ALS, FTD) 19. Therapeutic targets 20. Cellular stress response.
1. Bone marrow 2. Hematopoiesis 3. Adult stem cells 4. Macrophages 5. Monocytes 6. Phagocytosis 7. Immune system 8. Inflammation 9. Tissue repair 10. Regulatory T-cells 11. Cytokine production 12. Microenvironment 13. Monocyte differentiation 14. Macrophage activation 15. antigen presentation 16. Hematopoietic lineage 17. Macrophage subsets 18. Granulocyte-macrophage colony-stimulating factor (GM-CSF) 19. Colony-forming unit-macrophages (CFU-Macs) 20. Macrophage homeostasis
1. Breast cancer 2. Genetic factors 3. Development 4. Exclusively 5. Genetic predisposition 6. DNA mutations 7. Hereditary traits 8. BRCA1/2 genes 9. Familial breast cancer 10. Epigenetics 11. Environmental influences 12. Genetic testing 13. Risk assessment 14. Genetic counseling 15. Gene-environment interactions 16.孟德尔遗传规律 17.非随机性遗传 18.遗传易感性 19.分子遗传学 20.预防和早期筛查
1. CCL19 absence 2. DLNs (dendritic lymph node stem cells) 3. Immune response 4. T cell activation 5. Regulatory T cells (Tregs) 6. Inflammation调节 7. T helper cell function 8. Tumor microenvironment 9. Autoimmune disorders 10. Normal immune homeostasis 11. Immunoregulatory molecules 12. T cell differentiation 13. Dendritic cell signaling 14. Stromal cells in lymph nodes 15. Leukocyte trafficking 16. Chemokine CCL19 17. Lymph node development 18. Immune checkpoint inhibition 19. Transplant rejection 20. Chronic diseases
1. Unrelatedness 2. Breast cancer negation 3. Chk2 exclusion 4. Non-cancer association 5. Breast cancer-free 6. Chk2 function study 7. Breast tumor negative 8. No chk2 link to breast cancer 9. Chk2 biomarker analysis 10. Chk2 genetic association research 11. Breast cancer risk assessment 12. Chk2 role in breast health 13. Chk2 absence in cancer context 14. Breast cancer screenings 15. Chk2 null mutation 16. Breast cancer prevention 17. Breast cancer control 18. Chk2 and breast cancer meta-analysis 19. Breast cancer biomarker validation 20. Chk2 as a therapeutic target (anti-cancer focus)
1. Methylation age 2. DNA methylation 3. Cellular aging 4. Telomere length 5. CpG sites 6. Epigenetic clock 7. DNA hypomethylation 8. DNA hypermethylation 9. Genomic imprinting 10. Aging-related genes 11. Age acceleration 12. Methylation patterns 13. Senescence markers 14. Methylation clock 15. Cytosine DNA modification 16. Methylation dynamics 17. Telomeric DNA methylation 18. Methylation biomarkers 19. Aging research 20. Epigenetic dysregulation.
1. CRP (C-reactive protein) 2. Postoperative mortality 3. Coronary artery bypass graft (CABG) surgery 4. Prognostic value 5. Predictive marker 6. Inaccuracy 7. Mortality rate 8. Surgical outcome 9. Risk assessment 10. Bypass graft survival 11. Complications 12. Non-inferiority study 13. Cardiac surgery complications 14. Statistical significance 15. Cardiac biomarker 16. Clinical trial 17. Early warning sign 18. Sequential analysis 19. Follow-up mortality 20. Surgical risk factors
1. CX3CR1 2. Th2 cells 3. T cell survival 4. Immune response 5. Inflammation 6. Regulatory T cells (Tregs) 7. Cytokines 8. Cell migration 9. Chronic inflammation 10. Allergic reactions 11. Autoimmunity 12. Immunosuppression 13. T cell homeostasis 14. Chemokine receptor 15. T helper 2 (Th2) polarization 16. T cell activation 17. Convergent signaling 18. T cell exhaustion 19. Adenosine triphosphate (ATP) depletion 20. Apoptosis induction.
1. CX3CR1 2. Th2 cells 3. T cell survival 4. Cytokine signaling 5. Immunoregulation 6. T helper 2 (Th2) polarization 7. Chemokine receptor 8. Inflammation control 9. Regulatory T cells (Tregs) 10. Immune response 11. Antigen presentation 12. T cell homeostasis 13. Th2 cytokines (IL-4, IL-5, IL-13) 14. CD4+ T cells 15. Adhesion molecule 16. Conventional T cells (CD4+ CD8-) 17. Chronic inflammation 18. T cell proliferation 19. Adaptive immune response 20. Regulatory environment.
1. CX3CR1 2. Th2 cells 3. Airway inflammation 4. Immune response 5. Allergic asthma 6. Asthma exacerbation 7. T-helper 2 (Th2) polarization 8. Leukotrienes 9. Interleukin-4 (IL-4) 10. Interleukin-13 (IL-13) 11. Eosinophils 12. Mast cells 13. Th2 cytokines 14. Pro-inflammatory chemokine 15. Airway hyperreactivity 16. Allergic bronchitis 17. Lung inflammation 18. Immune privilege 19. Th2-driven inflammation 20. Regulatory T-cells (Tregs) balance.
1. CX3CR1 2. Th2 cells 3. Airway inflammation 4. Suppression 5. Immunoregulation 6. Allergic response 7. Asthma 8. Inflammatory cytokines 9. T-helper 2 (Th2) differentiation 10. Immune tolerance 11. Regulatory T-cells (Tregs) 12. Chemokine receptor 13. Airway hyperresponsiveness 14. Lung inflammation 15. Allergic asthma 16. Eicosanoids 17. Immune cell trafficking 18. Pro-inflammatory molecules 19. Tumor necrosis factor-alpha (TNF-α) 20. Interleukin-4 (IL-4) and -13 (IL-13)
1. Alcohol Aldehyde Dehydrogenase (ALDH) deficiency 2. Genetic mutation 3. __carrier status__ 4. Reduced alcohol metabolism 5. Low alcohol tolerance 6. Impaired alcohol detoxification 7. Non-carrier individuals 8. Healthy ALDH function 9.喝少量酒 10.适度饮酒 11.酒精依赖风险 12.酒精中毒预防 13.遗传性酒量小 14.健康生活方式 15.遗传咨询 16.药物辅助代谢 17.适量饮酒教育 18.筛查与诊断 19.遗传性酒量测试 20.酒精成瘾防控
1. Cataract 2. Trachoma 3. Primary cause 4. Blindness 5. Southern Sudan 6. Public health concern 7. Preventable blindness 8. Vision impairment 9. Eye diseases 10. Diarrheal infection 11. Nodular chlamydiasis 12. Community health initiative 13. Surgical intervention 14. Vision screening 15. Control programs 16. Eyecare services 17. Epidemiology 18. Preventive ophthalmology 19. Mass eye health campaign 20. Global blindness statistics
1. Cell autonomous sex determination 2. Somatic cells 3. Non-genetic sex determination 4. Galliformes (birds) 5. Avian biology 6. Sexual differentiation 7. Epigenetics 8. Hormonal regulation 9. Genomic imprinting 10. Zygote specification 11. Developmental genetics 12. Prenatal sex allocation 13. Mullerian and SRY genes 14. Sexual identity in birds 15. Testis-determining factor (TDF) 16. Female-biased sex determination 17. Male-biased sex determination 18. Anatomic sex distinction in birds 19. Environmental influences 20. Sexual dimorphism in galliforms.
1. Cell autonomous 2. Sex determination 3. Somatic cells 4. Passeriformes 5. Developmental biology 6. Genetic regulation 7. Sexual differentiation 8. Epigenetics 9. Hormonal control 10. Genomic imprinting 11. Mitotic choice 12. Tissue-specific mechanisms 13. Sexual identity 14. Zygotic and pre-zygotic mechanisms 15.小鸟 (Passeriformes specific) 16. Evolutionary study 17. Species-specific analysis 18. Genotypic and phenotypic variation 19. Sexual teleomorphism 20. Developmental genetics.
1. Bacillus subtilis 2. Sporulation 3. Defect 4. Cellular deficiency 5. Clpc (Cellular localization protein C) 6. Sporulation efficiency 7. Genetic mutation 8. Cell cycle progression 9. Spore formation 10. Vegetative growth 11. Diploid state 12. Sporeless phenotype 13. DNA replication 14. Mitosis 15. Cell wall synthesis 16. Spore biogenesis 17. Cell wall integrity 18. Spore stability 19. Bacterial genetics 20. Molecular biology in bacteria.
1. Methionine restriction 2. Cellular metabolism 3. Metabolic stress 4. MicroRNAs (miRNAs) 5. Gene expression regulation 6. Epigenetic modifications 7. Transcriptional silencing 8. miRNA response elements 9. Methylation patterns 10. Methylation-induced repression 11. Target genes 12. Methioneine-responsive miRNAs 13. Methylation-sensitive pathways 14. Protein translation 15. Cellular homeostasis 16. Cell cycle regulation 17. Developmental pathways 18. Aging and longevity 19. Cancer biology 20. Nutritional genetics.
1. Cellular aging 2. Skin aging 3. Anti-aging 4. Wrinkles 5. Fine lines 6. Graying hair 7. Age spots 8. Loss of elasticity 9. Skin texture 10. Melanin production 11. Collagen degradation 12. Telomere shortening 13. Aging signs 14. Aging process 15. Genetic factors 16. Environmental damage 17. Anti-aging products 18. Dermatological rejuvenation 19. Anti-ager treatments 20. Youthful appearance.
1. Chenodeoxycholic acid (CDCA) 2. Treatment 3. Whole body energy expenditure 4. Metabolic rate boost 5. Fat oxidation 6. Thermogenesis 7. Fatty acids metabolism 8. Weight loss 9. Calorie burn 10. Inulin fermentation 11. Inflammatory bowel disease (IBD) 12. Cholesterol management 13. Hyperlipidemia 14. Anti-obesity effects 15. Energy homeostasis 16. Exercise response 17. Nutrient absorption 18. Health benefits 19. Clinical trials 20. Drug therapy.
1. Chenodeoxycholic acid (CDCA) 2. Whole-body energy expenditure 3. Metabolic optimization 4. Fat metabolism 5. Weight loss 6. Thermogenesis 7. Calorie burn 8. Incretin hormones 9. Cholesterol management 10. Hyperlipidemia 11. Inflammatory response 12. Insulin sensitivity 13. Anti-obesity effects 14. Energy balance 15. Drug therapy 16. Clinical trials 17. Safety and efficacy 18. Body composition changes 19. Non-pharmacological intervention 20. Dietary supplementation
1. Chronic exercise 2. Endothelial function 3. Vasodilation 4. Nitric oxide (NO) 5. Nitric oxide synthase (NOS) 6. Nitric oxide-dependent mechanisms 7. Blood vessel dilation 8. Improved circulation 9. Oxidative stress reduction 10. Inflammation modulation 11. Angiotensin-converting enzyme (ACE) inhibition 12. Nitric oxide bioavailability 13. Exercise-induced angiogenesis 14. Enhanced endothelial progenitor cells 15. Nitric oxide release 16. Nitric oxide-dependent relaxations 17. Cardiac health 18. cerebrovascular benefits 19. Exercise training 20. Cardiovascular disease prevention.
1. Bat population 2. Cold weather patterns 3. hibernation onset 4. torpor induction 5. winter dormancy 6. foraging behavior 7. roost selection 8. food availability 9. chilling effect 10. habitat choice 11. birthing season 12. bat migration 13. reproductive cues 14. thermoregulation strategies 15. ice formation 16. thermal microclimates 17.冻土层利用 18. cold tolerance 19. predation avoidance 20. environmental variability.
1. Cold stress 2. Bat hibernation 3. Freezing temperatures 4. Lower reproductive success 5. Altered foraging behavior 6. Energy conservation 7. Torpor duration 8. Habitat choice 9. Bat population dynamics 10. Wintertime conditions 11. Climate change impacts 12. Thermoregulation 13. Bat emergence patterns 14. Food availability 15. Survival rates 16. Reproductive cycle 17. Cryobiology 18. Tundra or boreal ecosystems 19. Snow cover 20. Cold tolerance assessment
1. Nicotine replacement therapy (NRT) 2. Varenicline 3. Bupropion 4. Long-term abstinence 5. 52-week follow-up 6. Combined therapy 7. Dual therapy 8. Combined NRTs 9. Varenicline monotherapy 10. Bupropion monotherapy 11. quitting smoking 12. Smoking cessation 13. Quitting aids 14. Comprehensive addiction treatment 15. Enhanced efficacy 16. Higher success rates 17. Comparative study 18. Randomized controlled trials 19. Longitudinal analysis 20. Behavioral modification support.
1. Combined therapy 2. Kinase inhibitors 3. MEK inhibitors 4. KRAS mutation 5. Tumor treatment 6. Cancer targeting 7. Signaling pathway blocking 8. BRAF/MEK axis 9. Epidermal growth factor receptor (EGFR) inhibition 10. Metastatic colorectal cancer 11. Pan-cancer approach 12. Preclinical studies 13. Clinical trials 14. Cancers with wild-type EGFR 15. Targeted combination medicine 16. Inhibitor synergism 17. Anti-tumorigenic effect 18. K-Ras-driven tumors 19. Epithelial-mesenchymal transition (EMT) inhibition 20. Cancer immunotherapy augmentation.
1. Commelina yellow mottle virus (COMYMV) 2. Genome 3. 7489 base pairs 4. Sequence 5. DNA 6. RNA 7. Plant virus 8. Viral genetics 9. Genome structure 10. Genome composition 11. Genetic makeup 12. Codon count 13. Genetic code 14. Nucleotide sequence 15. Genome analysis 16. Genomic organization 17. Replication cycle 18. Transmission 19. Host range 20. Genetic variability 21. Infection symptoms 22. Antigenic properties 23. Phylogenetic analysis 24. Taxonomy 25. DNA sequencing technology 26. PCR (polymerase chain reaction) 27. Gene identification 28. Insertions/deletions (indels) 29. Substitution patterns 30. Evolutionary studies.
1. Crossover hotspots 2. Gene promoters 3. Saccharomyces cerevisiae 4. Yeast genome 5. DNA recombination 6. Genetic mapping 7. Chromosomal rearrangements 8. Non-coding regions 9. Promoter sequences 10. Regulatory elements 11. Transcription start sites (TSS) 12. Enhancers 13. Silencers 14. Centromeres 15. Telomeres 16. Chromosome arms 17. Homologous recombination 18. Meiosis 19. Genomic localization 20. Functional analysis in yeast.
1. Dendritic cells (DCs) 2. Innate lymphoid cells (ILCs) 3. Crosstalk 4. Intestinal homeostasis 5. Immune regulation 6. T cell activation 7. Antigen presentation 8. Immune response 9. Gut inflammation 10. Microenvironmental cues 11. Co-stimulatory signals 12. Cytokine secretion 13. Regulatory T cells (Tregs) 14. Natural killer cells (NKs) 15. DC-ILC interactions 16. Intestinal immune tolerance 17. Mucosal immunity 18. Th1/Th2 balance 19. DC maturation 20. Immune cell communication.
1. Cytochrome c 2. Mitochondrial intermembrane space 3. Cytosol 4. Apoptosis 5. Release 6. Mitochondrial dysfunction 7. Pro-apoptotic events 8. Bcl-2 family proteins 9. Caspase activation 10. Endoplasmic reticulum stress 11. Perinuclear clustering 12. Annihilation of mitochondria 13. Cytochrome c oxidase inhibition 14. Cytochrome c-dependent signaling 15. Apoptotic cascade 16. Mitochondria-mediated cell death 17. Cytosolic calcium increase 18. Mitochondria membrane permeabilization (MMP) 19. Soluble cytochrome c 20. Autophagy-related protein 8 (ATP504) or Omi-Histone deacetylase complex (Oxi-CD95L) involvement.
1. Cytosolic proteins 2. Iron-responsive elements (IREs) 3. Messenger RNA (mRNA) 4. DMT1 (Dopamine-metabolizing enzyme 1) 5. Iron uptake proteins 6. Iron homeostasis 7. Gene expression 8. Transcriptional regulation 9. Iron-responsive promoters 10. Enhancer elements 11. Iron binding affinity 12. Translation initiation 13. Post-transcriptional modifications 14. Iron transporters 15. Ferroportins 16. Ferritin 17. Hemoglobin 18. Hypoxia-inducible factor (HIF) 19. Iron-regulated genes 20. Cellular response to iron deficiency/abundance.
1. DMRT1 2. Sex determining gene 3. Epigenetic regulation 4. Mhm region 5. Genomic imprinting 6. DNA methylation 7. Chromatin remodeling 8. Histone modifications 9. Transcriptional silencing 10. Gene expression control 11. Sexual development 12. Genotype-phenotype relationship 13. dosage compensation 14. Developmental biology 15. X-inactivation 16. Sex-specific gene expression 17. Mammalian genetics 18. Epigenetic mark 19. Methylated DNA 20. Regulatory element.
1. De novo assembly 2. Sequence data 3. Specific contigs 4. Assembled sequences 5. Unassembled data 6. Genome sequencing 7. DNA拼接 8. Genome reconstruction 9. Contig length and quality 10. Genome completeness 11. Scaffold generation 12. Transcriptome analysis 13. Metagenomic assembly 14. Long-read sequencing 15. Error correction 16. Reference-based assembly 17. Consensus building 18. High-confidence regions 19. Short-read mapping 20. Genomic diversity analysis
1. Deamination 2. Cytidine 3. Uridine 4. Minus strand 5. Viral DNA 6. Catastrophic 7. G-to-A mutation 8. Genetic mutation 9. Viral genome 10. DNA base change 11. Nucleotide conversion 12. Post-transcriptional modification 13. Reverse transcriptase activity 14. RNA virus replication 15. Error-prone process 16. DNA damage 17. Mutagenesis 18. HIV (human immunodeficiency virus) 19. Herpesviruses 20. Hepatitis B virus (HBV)
1. Raptor deletion 2. Csf reduction 3. Neurological impact 4. Neurotransmitter function 5. Cognitive decline 6. Neuroinflammation 7. Neurodegeneration 8. Hematopoietic stem cells 9. Hematopoietic stem cell transplantation 10. Hematopoietic progenitor cells 11. G-CSF (Granulocyte-colony stimulating factor) 12. Hematopoietic regeneration 13. Cell therapy 14. Neuroprotective agents 15. Neurological rehabilitation 16. Animal model studies 17. Cognitive performance assessment 18. Brain atrophy 19. Regulatory T-cells 20. Immune modulation.
1. Deletion 2. V8 3. Spontaneous inflammatory phenotype 4. Genetic modification 5. Gene deletion 6. Functional analysis 7. Inflammation 8. Cell response 9. Molecular biology 10. Immunology 11. Cellular signaling 12. Genetic engineering 13. Pathogenesis 14. Gene editing 15. Phenotypic rescue 16. Loss-of-function study 17. Innate immune system 18. Adaptive immune response 19. Tissue inflammation 20. Genetic knock-out.
1. Dexamethasone 2. Postoperative bleeding 3. Risk reduction 4. Anesthesia recovery 5. Surgical complications 6. Hemorrhage prevention 7. Anti-inflammatory drug 8. Corticosteroid therapy 9. Blood clotting 10. Perioperative care 11. Critical care 12. Trauma surgery 13. Cardiac surgery 14. Orthopedic procedures 15. Gynecological surgeries 16. Transplantation 17. Analgesia 18. Immunosuppression 19. Prophylactic use 20. Bleeding prophylaxis.
1. Diabetic patients 2. Acute Coronary Syndrome (ACS) 3. Increased risk 4. Short-term bleeding events 5. Long-term bleeding complications 6. Cardiovascular health 7. Hemorrhagic complications 8. Blood glucose control 9. Anticoagulation therapy 10. Platelet function 11. Thrombocytopenia 12. Antiplasminogen antibodies 13. Drug interactions 14. Medications for ACS 15. Antiplatelet drugs 16. Bleeding management in diabetes 17. PCI (percutaneous coronary intervention) 18. Coronary artery bypass surgery 19. Cardiovascular emergencies 20. Prophylactic measures 21. Clinical trials 22. Risk stratification 23. Complication prediction 24. Longitudinal studies 25. Health outcomes research.
1. Translation initiation 2. Discrimination between initiators 3. Elongation transfer RNA (tRNA) 4. Initiation factor IF3 5. Genetic code translation 6. Ribosomal subunit assembly 7. Metagene analysis 8. Aminoacyl-tRNA binding 9. Transcriptional regulation 10. mRNA scanning 11. Elongation factor 3 (EF3) 12. Initiation complex formation 13. tRNA selectivity 14. Post-transcriptional modification 15. Transfer RNA charging 16. mRNA wobble base pairing 17. Initiation factors roles 18. tRNA-dependent protein synthesis 19. Signal recognition particle (SRP) interaction 20. Translation initiation factors IF3 function.
1. Downregulation 2. Mislocalization 3. Scribble protein 4. Cell transformation 5. Mammary tumorigenesis 6. Epigenetic regulation 7. Signal transduction 8. Cell adhesion 9. Cadherin function 10. cytoskeleton organization 11. Integrin signaling 12. Wnt/β-catenin pathway 13. Cytoskeletal dynamics 14. Cell polarity disruption 15. Loss-of-function studies 16. Genetic modifications 17. Tumor suppressor mechanism 18. Genomic instability 19. Metastasis prevention 20. Cancer prevention strategies.
1. Primary immune response 2. Early antibody production 3. Activated B cells 4. Migrations 5. Inner and outer paracortical regions 6. Oxysterol accumulation 7. Stromal cells 8. Immune tissue architecture 9. Tissue localization 10. Cortical lymphoid tissue 11. Germinal centers 12. Humoral immunity 13. Antigen-presenting cells (APCs) 14. Cytokine signaling 15. Differential chemotaxis 16. Immune cell trafficking 17. Lymphatic drainage 18. Spleen or lymph node 19. Immunoglobulin synthesis 20. Antigen-specific activation.
1. Enhanced production 2. Early inflammation 3. Chemokines 4. Viral control 5. Lung infection 6. Immune response 7. Pro-inflammatory molecules 8. Chronic obstructive pulmonary disease (COPD) 9. Respiratory syncytial virus (RSV) 10. Influenza virus 11. Interleukin-8 (IL-8) 12. Interferon-gamma (IFN-γ) 13. Monocyte chemotactic protein-1 (MCP-1) 14. C-C motif chemokines (CCLs) 15. T-cell recruitment 16. Antiviral efficacy 17. Pulmonary immunity 18. Viral clearance 19. Innate immune activation 20. Therapeutic intervention.
1. Epidemiology 2. Noncommunicable diseases (NCDs) 3. Disease burden 4. Low economic settings 5. Prevalence 6. Global health 7. Developing countries 8. Health disparities 9. Chronic conditions 10. Cardiovascular diseases 11. Diabetes 12. Cancer 13. Respiratory illnesses 14. Neurological disorders 15. Lifestyle factors 16. Environmental influences 17. Access to healthcare 18. Health infrastructure 19. Multidisciplinary research 20. Health policy 21. Health security 22. Universal health coverage 23. Global health statistics 24. Health equity 25. Life expectancy.
1. Epigenetics 2. Modulating agents 3. EMA (Epigenetic Modifying Agents) 4. Cancer model system 5. Antitumor immune response 6. Tumor regression 7. DNA methylation 8. Histone modification 9. Chromatin remodeling 10. Gene expression regulation 11. Immune checkpoint inhibitors 12. Cancer immunotherapy 13. CpG islands 14. MicroRNAs 15. Histone acetylation/deacetylation 16. DNA methylation inhibitors 17. Histone lysine methyltransferases (HKMTs) 18. Histone demethylases (HDMTs) 19. DNA methyltransferase inhibitors (DNMTi) 20. T cell activation 21. Natural killer cells 22. CD8+ T cells 23. PD-L1/PD-L2 targeting 24. CAR-T cells 25. Immunomodulatory drugs.
1. Peripheral IV drug administration 2. Errors 3. Common occurrences 4. Bolus administration 5. Multiple-step medicine preparations 6. Complications 7. Medication administration errors 8. Intravenous infusion errors 9. Dispensing mistakes 10. Technique errors 11. Patient safety 12. Device compatibility issues 13. Dosage errors 14. Volume calculation mistakes 15. Infusion rate problems 16. Administration errors during setup 17. Monitoring difficulties 18. Training and education 19. Standard precautions 20. Prevention strategies 21. Root cause analysis 22. Quality control checks 23. Risk assessment 24. Medication reconciliation 25. Adverse drug events (ADEs) related to peripheral IV用药.
1. Ethanol 2. Stress 3. Expression 4. IBP (Isoleucine-Valine-Pheylalanine, a bacterial protein) 5. Bacteria 6. Gene regulation 7. Transcriptional response 8. Protein synthesis 9. Stress-induced changes 10. Metabolic pathway 11. Biochemical mechanism 12. Stress tolerance 13. Overexpression 14. Downregulation 15. Epigenetics 16. Post-transcriptional modifications 17. Microarray analysis 18. qRT-PCR (Quantitative Real-Time PCR) 19. Gene knockout 20. Functional studies.
1. Fine particulate matter (PM2.5) 2. Air pollution 3. Anxiety 4. Environmental health 5. Respiratory health 6. Cardiovascular disease 7. Cognitive function 8. Stress 9. Mental health effects 10. Pollen and allergens 11. Urbanization 12. Pollution exposure 13. Prevalence studies 14. Risk assessment 15. Epidemiology 16. Air quality index (AQI) 17. Anxiety disorders 18. Environmental stressors 19. Psychological impact 20. Health disparities 21. Climate change 22. Pollution-related illness 23. Population surveys 24. Children and adolescents 25. Aging population 26. Long-term exposure 27. Workplace exposure 28. Urban air pollution 29. Green spaces and pollution mitigation 30. Policy interventions.
1. Febrile seizures 2. Epilepsy 3. Threshold 4. Development 5. Age-related increase 6. Fever-induced seizures 7. Early-onset epilepsy 8. Neurological risk 9. Susceptibility 10. Epileptogenesis 11. Seizure history 12. Autoimmune encephalitis 13.热性惊厥 14. Post-ictal changes 15. Genetic predisposition 16. Epileptic disorder 17. Immune response 18. Neonatal seizures 19. Neurological evaluation 20. Neurological outcomes.
1. Febrile seizures 2. Epilepsy 3. Threshold for development 4. Childhood infections 5. Temperature-related seizures 6. Autoimmune encephalitis 7. Immune system response 8. febrile convulsions 9. Early-onset epilepsy 10. Heat stroke 11. Fever-induced seizures 12. Neurological complications 13. Risk factor 14. Post-seizure syndrome 15. Epileptic disorder association 16. Febrile seizure history 17. Neurological follow-up 18. Brain injury 19. Seizure susceptibility 20. Febrile episode and epilepsy link
1. Apolipoprotein E4 (APOE4) 2. Female carriers 3. Dementia 4. Genetic risk 5. Increased likelihood 6. Alzheimer's disease 7. Cognitive decline 8. Neurodegeneration 9. Genetic marker 10. ApoE4 allele 11. Late-onset Alzheimer's 12. Familial Alzheimer's 13. Brain health 14. Risk assessment 15. Neurological disorders 16. Alzheimer's prevention 17. Population genetics 18. Neurobiological effects 19. Cognitive impairment 20. Genetic counseling
1. Flexible molecules 2. Steric hindrance 3. Tumor microenvironment 4. Rigid molecules 5. Conformational flexibility 6. Compartmentalization 7. Drug delivery 8. Immune evasion 9. Tumor cell interaction 10. Bioavailability 11. Molecular size and shape 12. Hydrophobicity 13. Hydrogen bonding 14. Steric interference 15. Tumor microclimate 16. Drug resistance 17. Target recognition 18. Drug efficacy 19. Conformational change 20. Biochemical dynamics
1. Foxo3a 2. Neuronal death 3. Activation 4. Reactive oxygen species (ROS) 5. Signaling pathway 6. Mitochondrial dysfunction 7. Apoptosis 8. Oxidative stress 9. Free radicals 10. DNA damage 11. Calcium homeostasis 12. Endoplasmic reticulum stress 13. p53 pathway 14. Redox imbalance 15. Antioxidant defense 16. Nrf2 activation 17. Glutathione peroxidase 18. H2O2 19. Superoxide dismutase 20. Fenton reaction.
1. Free histones 2. Degradation 3. Rad53-dependent mechanism 4. DNA replication 5. DNA double-strand break repair 6. Checkpoint protein 7. ATM/ATR activation 8. H2A, H2B, H3, and H4 9. Histone eviction 10. Chromatin remodeling 11. Ubiquitin-proteasome system (UPS) 12. DNA damage response (DDR) 13. Telomere maintenance 14. G1/S checkpoint 15. DNA repair proteins 16. Phosphorylation events 17. Nucleotide excision repair (NER) 18. Homologous recombination (HR)
1. Myelodysplastic syndrome (MDS) 2. Genomic alterations 3. Functional consequences 4. Animal models 5. Poor understanding 6. Lack of appropriate models 7. Hematopoietic dysfunction 8. Genetic dysregulation 9. Bone marrow failure 10. Clonal expansion 11. Mutations in key genes 12. Disease pathogenesis 13. Cellular dysplasia 14. Hematologic disorders 15. Prognosis and therapy 16. Preclinical research 17. Mouse models for MDS 18. Transgenic models 19. Gene knockouts 20. Cell-based assays.
1. Zebrafish 2. Neuralation 3. Fz (Fasciclin-like protein) 4. Pcp (Protein CUB-16) 5. Dependent localization 6. Anterior membrane 7. Neuroectoderm cells 8. Developmental process 9. Cell differentiation 10. Gene expression 11. Neural progenitors 12. Embryonic stage 13. Focal adhesion complex 14. Epidermal growth factor receptor signaling 15. Wnt/β-catenin pathway 16. Neural tube formation 17. Cell migration 18. Cranial organizer 19. Neural crest migration 20. Mesoderm-ectoderm boundary.
1. Fz (Fibroblast growth factor) 2. Pcp (Patched protein, a signaling component) 3. Dependent (interaction or regulation) 4. PK (Protein kinase, involved in signaling pathways) 5. Localizes to (position or localization) 6. Anterior membrane (innermost layer of the notochord) 7. Notochord cells (specialized cell type in the embryo) 8. Zebrafish (model organism) 9. Neuralation (process of neural development) 10. Embryonic stage 11. Developmental biology 12. Signaling cascade 13. FGF (fibroblast growth factor signaling) 14. Notochord differentiation 15. Mesoderm formation 16. Tissue-specific expression 17. Cell adhesion 18. Morphogenesis.
1. GATA-3 2. Hematopoietic stem cells (HSCs) 3. Stem cell function 4. Development 5. Differentiation 6. Blood production 7. Immune system 8. Regulatory genes 9. Cell cycle control 10. Self-renewal 11. Hematopoiesis 12. Lineage commitment 13. Transcription factor 14. T-cell lineage 15. Lymphoid lineage 16. Myeloid lineage 17. Hematopoietic lineage 18. Immunoglobulin gene rearrangement 19. Cancer stem cells 20. Hematologic disorders.
1. Gene expression consistency 2. Identical genetic background 3. No significant variation 4. Homologous cells 5. Equivalent expression levels 6. No genetic diversity effect 7. No cellular differentiation 8. Parallel gene expression 9. Genetic stability 10. No allelic difference impact 11. Isogenic cell line 12. No epigenetic variation 13. No cell-to-cell variation 14. Homogenous transcriptome 15. Genetic control of expression 16. No genetic drift 17. Identical DNA sequence 18. No genetic polymorphism 19. No genetic variation in regulation 20. Functional equivalence among cells.
1. Glycolysis 2. Primary glycometabolic pathway 3. Cellular metabolism 4. Metabolism of carbohydrates 5. Glucose metabolism 6. ATP production 7. Energy generation 8. Citric acid cycle (Krebs cycle) 9. TCA cycle 10. Anaerobic respiration 11. Lactic acid fermentation 12. Glycogen breakdown 13. Glycogenolysis 14. Glucose-6-phosphate 15. Phosphorylation reactions 16. Enzymatic process 17. hexokinase 18. Pyruvate kinase 19. Fermentation enzymes 20. Glycolytic shuttle 21. Glycolytic pathway regulation 22. Metabolic control points 23. Biochemistry 24. Cell biology 25. Medical science 26. Bioenergetics 27. Biochemistry textbooks 28. Science education 29. Cellular biochemistry 30. Glycolytic pathway function
1. Golli deficiency 2. T cells 3. Anergic phenotype 4. Adaptive immune response 5. Increased calcium (Ca2+) levels 6. Cytosol 7. Calcium homeostasis 8. Regulatory T cells (Tregs) 9. Immune tolerance 10. Autoimmune disorders 11. Parathyroid hormone-related protein (PTHrP) 12. Calcineurin signaling 13. T-cell activation 14. Intracellular calcium sensing 15. Antigen presentation 16. Calcium ion channels 17. Chronic inflammation 18. Hypocalcemia 19. Hypercalcemia 20. Calcium-binding proteins.
1. HNF4A mutations 2. Diabetes 3. Mutant carriers 4. Age of onset 5. 14 years 6. Genetic condition 7. Endocrine disorder 8. Pancreatic beta-cell dysfunction 9. Hyperglycemia 10. Insulin resistance 11. Type 1 diabetes 12. Type 2 diabetes 13. Congenital diabetes 14. Juvenile diabetes 15. Hormone nuclear factor 4 alpha (HNF4alpha) 16. Gene therapy 17. Early diagnosis 18. Genetic counseling 19. Preclinical research 20. Clinical significance.
1. Headaches 2. Cognitive impairment 3. Correlation 4. Neurological function 5. Brain health 6. Migraines 7. Tension headaches 8. Sinusitis 9. Stress-related headaches 10. Lack of correlation 11. Neurological disorders 12. Brain fog 13. Memory issues 14. Attention span 15. Executive function 16. Learning disabilities 17. Neurological exams 18. Brain scans 19. Normal cognition 20. Healthy brain function.
1. Healthcare delivery 2. Efficiency improvement 3. Crowded delivery centers 4. Structural logistics 5. Interpersonal elements 6. Process optimization 7. Supply chain management 8. Resource allocation 9. Workflow optimization 10. Facility design 11. Capacity planning 12. Staffing optimization 13. Patient flow control 14. Communication protocols 15. Technology integration 16. Inventory management 17. Queuing systems 18. Training and education 19. Emergency response planning 20. Performance metrics 21. Continuous improvement 22. Lean healthcare 23. Operational efficiency 24. Telemedicine 25. Remote patient monitoring
1. Helminths 2. Immune system 3. Macrophages 4. Interference 5. IL-4 (Interleukin-4) 6. Activation 7. Mycobacterium tuberculosis 8. Replication 9. Parasitic infections 10. T-helper 2 (Th2) response 11. Regulatory T-cells 12. Immunosuppression 13. granulomas 14. Tubercular infection 15. Mycobacterial infection 16. Cytokine balance 17. Inflammation modulation 18. Th1/Th2 imbalance 19. Immune evasion 20. Chronic inflammation.
1. Hematopoietic stem cells 2. Purification process 3. Purity rate 4. Up to 50% 5. Cell separation 6. Isolation techniques 7. Magnetic bead purification 8. Fluorescence-activated cell sorting (FACS) 9. Cell filtration 10. Mononuclear cell enrichment 11. Stem cell isolation 12. Blood processing 13. Apheresis 14. Gating strategy 15. Quality control 16. Clonal expansion 17. Stem cell therapy 18. Autologous transplantation 19. Allogeneic transplantation 20. Regulatory T cells 21. Hematopoietic progenitors 22. Precursor cells 23. Cell culture purity 24. Research applications 25. Clinical-grade purification.
1. Cardiopulmonary fitness 2. Increased mortality rate 3. Exercise and health 4. Heart health 5. Respiratory function 6. Cardiovascular disease 7. Fitness level 8. Survival rate 9. Chronic obstructive pulmonary disease (COPD) 10. Asthma 11. Allergies 12. Hypertension 13. Risk factors 14. Life expectancy 15. Fitness assessment 16. Exercise guidelines 17. Aging population 18. Cardiac workout 19. Pulmonary exercise 20. Mortality statistics.
1. Dietary calcium 2. Secondary hyperparathyroidism 3. Prevention 4. Intakes 5. 25-OH D levels 6. Normal range 7. 75 nmol/L 8. Hyperparathyroidism 9. Calcium supplementation 10. Bone health 11. Vitamin D deficiency 12. Parathyroid gland function 13. Risk assessment 14. Calcium homeostasis 15. Healthy bones 16. Calcium intake guidelines 17. Renal function 18. Calcium-restricted diets 19. Iodine status 20. Calcium-PTH balance.
1. Chronic obstructive pulmonary disease (COPD) 2. CRP (C-reactive protein) 3. Exacerbations 4. Risk reduction 5. Inflammation 6. Lung function 7. Airway inflammation 8. COPD exacerbations management 9. COPD control 10. Pulmonary inflammation 11. Biomarker 12. Low CRP levels 13. COPD therapy 14. Anti-inflammatory strategies 15. Pulmonary rehabilitation 16. COPD flare-ups 17. COPD severity 18. Prognosis 19. Chronic inflammation 20. COPD complications.
1. Copeptin 2. High levels 3. Diabetes 4. Risk reduction 5. Metabolic syndrome 6. Inflammation 7. Insulin resistance 8. Glucose control 9. Hypertension 10. Cardiovascular health 11. Stress hormones 12. Autoimmune response 13. Adipokine balance 14. Diabetic complications 15. Chronic stress 16. Hormonal regulation 17. Anti-inflammatory peptides 18. Weight management 19. Diabetes prevention 20. Clinical research
1. High sensitivity cardiac troponin T (hs-cTnT) 2. Shortened time frame (less than 3 hours) 3. Acute myocardial injury (AMI) 4. Diagnostic threshold 5. Hsct T dosage 6. Early onset symptoms 7. Myocardial infarction 8. Cardiac biomarker testing 9.临诊意义 10. Subacute presentation 11. Time-dependent sensitivity 12. Cardiac injury assessment 13. Emergency care 14. Prompt diagnosis 15. In-hospital evaluation 16. Cardiac ischemia 17. Rule-out criteria 18. Rapid cardiac assessment 19. Cardiac troponin T levels 20. Emergency medical service (EMS) interpretation.
1. Histone demethylase 2. Recruitment 3. Transient decrease in methylation 4. Nuclear receptors 5. Ligand-dependent induction 6. Transcription activation 7. Epigenetic regulation 8. H3K9/14 methylation 9. H3K27 methylation 10. Enhancer histone marks 11. Corepressor proteins 12. Coactivator recruitment 13. Chromatin remodeling 14. Signal transduction 15. Transcriptional repression 16. Activation domain 17. Hormone response elements (HREs) 18. DNA binding specificity 19. Dynamic epigenome 20. Gene expression control.
1. Homozygous deletion 2. Murine SBDS gene 3. Osterix-expressing mesenchymal stem cells (OMSCs) 4. Progenitor cells (MPCs) 5. Oxidative stress 6. Prevention 7. Genetic engineering 8. Stem cell biology 9. Mesenchymal differentiation 10. Gene therapy 11. Functional analysis 12. Cell viability 13. Stress resistance 14. Mitochondria dysfunction 15. ROS (reactive oxygen species) 16. DNA damage 17. Cell protection 18. Mouse model 19. Stem cell niche 20. Senescence prevention.
1. Human T lymphotropic virus type I (HTLV-1) 2. Myelopathy 3. Tropical Spastic Paraparesis (TSP) 4. Ham/TSP patients 5. Immunoglobulin G (IgG) 6. Cross-reactivity 7. Immunodominant epitope 8. Tax protein 9. HTLV-1 infection 10. Chronic infection 11. Neurological complications 12. Immune response 13. Autoimmune reaction 14. Seropositivity 15. Specific antibody detection 16. HTLV-1-associated immune dysfunction 17. T-cell activation 18. Cytotoxic T-lymphocytes 19. HTLV-1 Tax-specific antibodies 20. Diagnosis and screening.
1. Hyperfibrinogenemia 2. Thrombosis 3. Femoropopliteal bypass 4. Blood clots 5. Deep vein thrombosis (DVT) 6. Arterial thrombosis 7. Prothrombin time (PT) 8. International Normalized Ratio (INR) 9. Fibrinogen level 10. Risk factor 11. Anticoagulation therapy 12. Clot prevention 13. Thromboprophylaxis 14. Dilation and angioplasty 15. Surgery complications 16. Patient outcomes 17. Hypercoagulability 18. Hemorrhagic risk 19. Anti-fibrinolytic drugs 20. Cardiovascular disease (CVD) management.
1. Hyperfibrinogenemia 2. Femoropopliteal bypass 3. Thrombosis 4. Vascular surgery 5. Blood clot formation 6. Deep vein thrombosis (DVT) 7. Arterial thrombosis 8. Perioperative risk 9. Prothrombic state 10. Fibrinogen levels 11. Hypercoagulability 12. Thromboprophylaxis 13. Anticoagulation therapy 14. Risk factor 15. Bleeding complications 16. Cardiovascular disease 17. DVT prophylaxis 18. Embolic events 19. Postoperative thrombosis 20. Medical intervention.
1. Hypertension 2. Type 1 diabetes 3. Frequent occurrence 4. Coincidence 5. Diabetic hypertension 6. Complication 7. Diabetes and high blood pressure 8. Prevalence in diabetics 9. Risk factor 10. Endocrine connection 11. Diabetic nephropathy 12. Autonomic dysfunction 13. Microalbuminuria 14. Hyperinsulinemia 15. Glucose metabolism 16. Blood pressure control 17. Hypertensive crisis in diabetes 18. Chronic kidney disease 19. Cardiovascular disease 20. Diabetes management.
1. Hypocretin neurons 2. Panic-prone behavior 3. Rats 4. Induction 5. Stress response 6. Fear conditioning 7. Anxiety-like symptoms 8. Serotonin release 9. Hypertonia 10. Flight or fight response 11. Amygdala activation 12. Panic disorder 13. Hypocretinergic dysfunction 14. Acute stress tests 15. Hippocampus involvement 16. Behavioral changes 17. Hypocretin receptor modulation 18. Panic attack simulation 19. Neurobiological mechanism 20. Animal model studies.
1. Hypoglycemia 2. Dementia 3. Risk factor 4. Glycemic control 5. Blood sugar levels 6. Brain health 7. Neurological decline 8. Cognitive impairment 9. Alzheimer's disease 10. Parkinson's disease 11. Diabetes-related dementia 12. Severe hypoglycemia 13. Hypoglycemic episode 14. Insulin therapy 15. Glucose metabolism 16. Brain atrophy 17. Cognitive dysfunction 18. Diabetes complications 19. Elderly population 20. Long-term care.
1. Hypothalamus 2. Glutamate 3. Neurotransmission 4. Energy balance 5. Metabolic regulation 6. Body weight 7. Hunger/satiety 8. Fatigue/energy homeostasis 9. Brain-pituitary-adrenal (HPA) axis 10. Hormonal control 11. Neuronal signaling 12. Ion channels 13. Excitatory neurotransmitter 14. Glutamatergic receptors 15. Leptin 16. Ghrelin 17. Thermoregulation 18. Sleep-wake cycle 19. Food intake 20. Fat metabolism.
1. Viral replication 2. Sequestration 3. Mis-capped RNAs 4. IFIT1 (Interferon-induced transmembrane protein 1) 5. Antiviral mechanism 6. RNA interference 7. Capping machinery 8. Host defense 9. Non-productive infection 10. RNA stability 11. Virus-host interactions 12. Innate immune response 13. dsRNA recognition 14. Type I interferons 15. Capsid recognition 16. Antisense action 17. RNA degradation 18. Membrane association 19. Viral gene silencing 20. RNA interference pathway.
1. IRG1 2. Antiviral activity 3. Neurotropic viruses 4. Viral infection 5. Immune response 6. Innate immunity 7. IFN-gamma-regulated gene 1 8. Virus replication inhibition 9. Neuroprotection 10. Gammaherpesviruses 11. Cytosine-guanosine deaminase 12. HSV (Herpes simplex virus) 13. HIV (Human immunodeficiency virus) 14. rabies virus 15. Encephalitis 16. Neurological protection 17. Antiviral drug target 18. Gene therapy 19. Innate immune response genes 20. Neurological disease prevention.
1. ITAM (Immunoreceptor Tyrosine-Based Motif) 2. Phosphorylation 3. T Cell Receptor (TCR) 4. Echo Domain 5. Cytoplasmic Tail 6. Signal transduction 7. TCR activation 8. Intracellular cascade 9. CD3 complex 10. T cell signaling pathway 11. Tyrosine kinase activation 12. Positive regulation 13. Protein-protein interaction 14. Zeta chain (CD3z) 15. Downstream effects 16. Signal integration 17. Antigen recognition 18. Cytokine release 19. T cell activation markers 20. T cell proliferation.
1. Iga plasma cells 2. Transglutaminase 2 (Tg2) 3. Gluten-free diet 4. Duodenal mucosa 5. Specific accumulation 6. Autoimmune response 7. Gluten sensitivity 8. Immunoglobulin A (IgA) antibodies 9. Mucinosis 10. Coeliac disease 11. Intestinal inflammation 12. Tissue transglutaminase 2 (tTG2) 13. Endomysial antibody (EMA) 14. Duodenal biopsy 15. Gluten-related enteropathy 16. Lactose intolerance 17. Gluten-free celiac-like syndrome 18. Small intestinal damage 19. Serotonin-associated IgA deposits 20. Gluten tolerance disorder.
1. Immune complex 2. Cell death 3. Extracellular release 4. Neutrophil protein 5. High Mobility Group Box 1 (HMGB1) 6. Inflammation 7. Activation 8. Phagocytosis 9. Chronic inflammation 10. Lysosomal degradation 11. Damage associated molecular patterns (DAMPs) 12. Pro-inflammatory cytokines 13. Endothelial dysfunction 14. Autocrine/paracrine signaling 15. Apoptosis 16. Necroptosis 17. NETosis (neutrophil extracellular trap) 18. Chronic tissue injury 19. Autoimmune diseases 20. Chronic inflammation-induced organ damage.
1. Immune responses 2. Inflammatory Th17 cells 3. Regulatory T cells (iTregs) 4. Adaptive immunity 5. Cytokines 6. Dendritic cells 7. T helper 17 (Th17) 8. T regulatory (Treg) cells 9. Immunosuppression 10. Chronic inflammation 11. T cell differentiation 12. Pro-inflammatory cytokines (IL-17, IL-23) 13. Anti-inflammatory cytokines (IL-10, TGF-β) 14. Regulatory networks 15. Tumor necrosis factor (TNF) 16. Interleukin-4 (IL-4) 17. Transforming growth factor-beta (TGF-β1) 18. Helicobacter pylori infection 19. Autoimmune diseases 20. Immunoregulatory therapies 21. Regulatory T cell function 22. Inducible Treg cells (iTregs) 23. Epithelial cells 24. Intestinal homeostasis 25. Adaptive immune tolerance.
1. T cells 2. Adult tissue 3. Memory T cells 4. Immune system 5. Primary T cells vs. memory T cells 6. Regulatory T cells 7. Epitope recognition 8. Chronic inflammation 9. Adaptive immunity 10. Lymphatic tissue 11. Somatic hypermutation 12. Cytotoxic T cells 13. HLA (human leukocyte antigen) 14. T cell differentiation 15. T cell homeostasis 16. T cell proliferation 17. T cell receptor repertoire 18. Germinal centers 19. T cell exhaustion 20. Cancer immunology 21. Organ-specific immunity 22. Secondary lymphoid organs (e.g., spleen, lymph nodes)
1. Saccharomyces cerevisiae 2. Domesticated populations 3. Whole chromosome aneuploidy 4. Uncommon occurrence 5. Genetic diversity 6. Normal karyotype 7. Polyploidies 8. Genetic stability 9. Haploidy vs. polyploidy 10. Fermentation yeast 11. Industrial brewing 12. Laboratory strains 13. Genetic mutation 14. Chromosomal instability 15. Genetic screening 16. Genetic engineering 17. Cerebral hypoplasia (in relation to rare cases) 18. Population genetics 19. Aneuploidy detection methods 20. Genetic basis of adaptation.
1. Mice 2. P. chabaudi 3. Parasites 4. Proliferation 5. Early infection 6. Inoculation 7. Lower numbers 8. High numbers 9. Host immune response 10. Parasite virulence 11. Infection kinetics 12. Parasite load 13. Mouse model 14. Experimental infection 15. Differential growth 16. Parasite adaptation 17. Quantitative analysis 18. Competitive advantage 19. Immune evasion 20. Parasite transmission.
1. Mouse models 2. Loss of CSF1R (CSF1 receptor) 3. Moz (Mucin-like protein 4, T-cell immunoglobulin and ITIM domain 2) 4. Induced leukemogenesis 5. Tumor-initiating factor 2 (TIF2) 6. Leukemia development 7. Hematopoietic stem cells 8. CSF1 signaling 9. Immune regulation 10. T-cell activation 11. Chronic myeloid leukemia (CML) 12. Pro-inflammatory environment 13. Genetic manipulation 14. Mouse genetic studies 15. Mouse model-based research 16. Mouse models of cancer 17. Tumor-promoting effects 18. Pathway analysis 19. Leukemia stem cells (LSCs) 20. Mouse models of CSF1R deficiency.
1. Transgenic mice 2. Green fluorescent protein (GFP) 3. Sox2 promoter 4. Cell proliferation markers 5. Colocalization analysis 6. Subcellular localization 7. Fluorescence microscopy 8. Quantitative assessment 9. Cell differentiation 10. Proliferative cells 11. Stem cell标记物 12. Tissue-specific expression 13. Gene targeting 14. GFP-expression pattern 15. Cell cycle progression 16. Progenitor cells 17. Epithelial-mesenchymal transition 18. Inducible gene expression 19. Minimal co-localization 20. Cell cycle arrest or suppression.
1. ADHD medications 2. Young and middle-aged adults 3. Current use 4. Remote use 5. Cardiovascular events 6. Risk assessment 7. Cardiac health 8. Heart disease 9. Congestive heart failure 10. Hypertension 11. Arrhythmia 12. Stroke 13. Drug safety 14. Cardiovascular side effects 15. Long-term use 16. Clinical trials 17. Population-based studies 18. Prevalence of medication use 19. Risk factors 20. Cardiovascular outcome research
1. Heart Failure Incidence 2. Women's Health Improvement 3. Decrease by 10% 4. Timeframe: 1979 to Present 5. Gender-specific trend 6. Cardiac Failure in Women 7. Statistical Analysis 8. Epidemiological Study 9. Longitudinal Data 10. Cardiovascular Health Equity 11. Temporal Change 12. Cardiovascular Risk Reduction 13. Heart Failure Prevention 14. Women's Cardiovascular Mortality 15. Medical Progress 16. Lifestyle Factors 17. Heart Disease in Women 18. Cardiovascular Intervention 19. Cardiovascular Medications 20. Public Health Policy.
1. Cervical cancer 2. Incidence rates 3. Decreased 4. Trend 5. Statistical decline 6. Global health 7. Screening programs 8. Vaccination coverage 9. Pap smear testing 10. Cancer prevention 11. Women's health 12. Risk factors reduction 13. Cancer control initiatives 14. Health policy 15. Epidemiological analysis 16. Time series data 17. Mortality statistics 18. cervical cancer burden 19. Early detection 20. Public health success
1. Cervical cancer incidence 2. Nationwide screening programs 3. Cytology testing 4. Uterine cervical cancer detection 5. Screening guidelines 6. Pap smear 7. Precancerous cervical lesions 8. Early detection rates 9. Cancer prevention initiatives 10. Incidence trends 11. Risk reduction 12. Cervical cancer screening coverage 13. HPV testing 14. Colposcopy 15. Cervical cancer awareness 16. National cervical cancer control program 17. Preventive healthcare policy 18. Early diagnosis 19. Screening frequency 20. Targeted population (e.g., women of reproductive age)
1. Microtubule acetylation 2. LRRK2 ROC (Rho-associated coiled-coil) domain 3. Mutations 4. Neurodegeneration 5. Locomotor deficits 6. Protein regulation 7. Parkinson's disease 8. Cytoskeleton dynamics 9. Acetyltransferases 10. Neuroprotective therapies 11. Motor function 12. Mitochondrial dysfunction 13. Protein stability 14. Protein aggregation 15. Signaling pathways 16. Neurobiology of movement 17. Cell cycle control 18.阿尔茨海默's-like symptoms 19. Therapeutic targets 20. Preclinical studies.
1. Vessel density 2. Fibrosis 3. Chemotherapy efficacy 4. Reduction 5. Tumor microenvironment 6. Drug resistance 7. Prognosis 8. Metastasis prevention 9. Angiogenesis 10. Peritumoral vasculature 11. Fibroblastic activation 12. Inflammation 13. Fibrosis regression 14. Anti-angiogenic therapy 15. Drug delivery 16. Tumor perfusion 17. Metabolic reprogramming 18. Cancer stem cells 19. Hypoxia 20. Efficacy decline
1. Low serum vitamin D 2. Increased risk 3. Multiple sclerosis 4. Vitamin D deficiency 5. Immune system 6. Neurodegenerative disease 7. Oxidative stress 8. Inflammation 9. Genetic predisposition 10. Environmental factors 11. Sun exposure 12. Diet 13. Calcium absorption 14. Bone health 15. Autoimmune disorder 16. MS symptoms 17. Laboratory testing 18. Disease progression 19. Prevention strategies 20. Nutritional interventions.
1. Human T-cell Lymphotropic Virus Type 1 (HTLV-1) 2. Infection 3. Frequency 4. African Origin 5. Ethnicity 6. HTLV-1 infection in Africans 7. Genetic predisposition 8. Chronic infection 9. Adult T-cell Leukemia-Lymphoma (ATLL) 10. HTLV-1 associated diseases 11. AIDS cofactor 12. HIV co-infection 13. HIV-1/HTLV-1 coinfection 14. Cytomegalovirus (CMV) co-reactivity 15. Epidemiology of HTLV-1 in Africa 16. HTLV-1 carrier rate 17. Risk factors 18. Life expectancy 19.和社会文化背景 20. Global health disparities.
1. Inositol lipid 3 phosphatase (IL3P) 2. PTEN (Phosphatase and Tensin Homolog) 3. Phosphatidylinositol 3,4,5-trisphosphate (PTDIs-3,4-P2) 4. Phosphatidylinositol 4-phosphate (PI4P) 5. Lipid signaling 6. Phosphatidylinositol metabolism 7. PI3K/Akt pathway 8. Negative regulation 9. Signal transduction 10. Cytosolic phospholipase D (CPLD) 11. Dephosphorylation 12. Membrane lipidomics 13. Cancer biology 14. Tumor suppressor 15. PI3K/PTEN axis.
1. Mental health professionals 2. Physical health care providers 3. Homelessness prevention 4. Client engagement 5. Treatment interventions 6. Behavioral therapy 7. Medication management 8. Supportive housing 9. Case management 10. Early intervention 11. Community-based care 12. Prevention strategies 13. Wellness programs 14. Access to care 15. Social work 16. Psychosocial services 17. Substance abuse treatment 18. Mental health awareness 19. Health education 20. Housing stability 21. Coordinated care 22. Peer support 23. Chronic illness management 24. Crisis intervention 25. Public health approach 26. Systematic evaluation 27. Policy advocacy 28. Homeless population 29. Housing first principle 30. Collaborative efforts
1. Insomnia 2. Effective treatment 3. Cognitive Behavioral Therapy (CBT) 4. Sleep disorders 5. Sleep disturbance 6. Sleep quality improvement 7. Behavioral therapy for insomnia 8. Cognitive therapy for sleep 9. Sleep pattern regulation 10.失眠症 management 11. Behavioral sleep习惯 change 12. Sleep hygiene education 13. Stress reduction through CBT 14. Anxiety and insomnia therapy 15. Phobias and insomnia treatment 16. Sleep apnea and CBT 17. Chronic insomnia management 18. Relaxation techniques for insomnia 19. Sleep deprivation relief 20. Sleep EEG or polysomnography (PSG) in CBT context.
1. Insulin 2. Severe kidney failure 3. Diabetes complications 4. Renal dysfunction 5. Hyperglycemia 6. Hypertension 7. Glomerulopathy 8. Diabetic nephropathy 9. Renal insufficiency 10. Hyperinsulinemia 11. Kidney damage 12. Chronic kidney disease (CKD) 13. Diabetic ketoacidosis (DKA) 14. Microalbuminuria 15. Glucose intolerance 16. Renal failure of diabetes 17. Renal replacement therapy 18. Pathophysiology 19. Risk factors 20. Medical prevention.
1. Classroom-based collaborative learning 2. Web-based collaborative learning 3. Integration 4. Learning outcomes 5. Subpar performance 6. Educational technology 7. Student engagement 8. Group dynamics 9. Distance education 10. Online collaboration 11. Learning effectiveness 12. Classroom-Internet synergy 13. Performance gap 14. Instructional design 15. Learning environments 16. Information and communication technology (ICT) 17. Task completion rates 18. Collaborative tools 19. Assessment and feedback 20. Hybrid learning models
1. Ivermectin 2. Lymphatic filariasis 3. Medical treatment 4. Parasitic infection 5. Wuchereria bancrofti 6. Onchocerca volvulus 7. Filarial worm disease 8.丝虫病 (in Chinese or other languages depending on the context) 9. Mass drug administration (MDA) 10. Vector control 11. Drug resistance 12. Prevention and control 13. Human lymphatic filariasis (HLF) 14. Treatment guidelines 15. Clinical trials 16. WHO recommended 17. Adult worm infection 18. Microfilariae detection 19. Secondary effects 20. Post-treatment follow-up
1. Ivermectin 2. Onchocerciasis 3. Medical treatment 4. Parasitic infection 5. Soil-transmitted disease 6. Hookworm infestation 7. Vector-borne disease 8. morbidity reduction 9. Filarial worms 10. Mass drug administration 11. Deworming therapy 12. Topical medication 13. Scabies prevention 14. River blindness 15. Control program 16. Drug resistance 17. Human lymphatic filariasis 18. Community-based interventions 19. Public health campaign 20. Treatment efficacy.
1. LDL cholesterol 2. Cardiovascular disease 3. Involvement 4. Development 5. Prevention 6. Risk factor 7. Low-density lipoprotein (LDL) 8. Heart attack 9. Stroke 10. Atherosclerosis 11. Cholesterol management 12. Hyperlipidemia 13. Statins 14. LDL-reducing medications 15. HDL cholesterol 16. LDL particle size 17. Lipoprotein(a)  18. Genetics 19. Lifestyle modifications 20. Cardiovascular health.
1. Bacillus subtilis 2. Sporulation 3. Clpc (Cleavage and Lysis Protein C) 4. Efficiency 5. Lack 6. Genetic mutation 7. Cellular process 8. Spore formation 9. Stress tolerance 10. Morphogenesis 11. Laboratory strain 12. Genetic engineering 13. Gene function 14. Cell division 15. Virulence 16. Stress response 17. Subtilis-specific mechanisms 18. Sporulation rate 19. Biofilm development 20. Laboratory experiments.
1. Gabonese children 2. Schimmelpenning-Feuerstein Mims Syndrome (SFM) 3. Plasma lactate 4. Less than 10 cases 5. SFM diagnosis 6. Elevated plasma lactate level 7. 5mmol/L threshold 8. Clinical presentation 9. Medical condition 10. Genetic disorder 11. Enzymatic defect 12. Lactic acidosis 13. Laboratory test 14. Metabolic impairment 15. Childhood onset 16. Neurological complications 17. Comprehensive assessment 18. Population-based study 19. Epidemiology 20. Treatment and management.
1. Leukemia 2. Rho Guanine Nucleotide Exchange Factor (RhoGEF) 3. Repression 4. RhoA 5. Src Activation 6. Signal transduction 7. Cellular signaling 8. Cytoskeleton regulation 9. Cell cycle control 10. Pro-inflammatory response 11. Tumor suppressor 12. Gene expression modulation 13. Signal integration 14. Rho GTPase pathway 15. Cellular transformation 16. Oncogenic pathways 17. RhoA activity inhibition 18. Integrin activation 19. cytoskeletal dynamics 20. Cancer biology.
1. Leukoencephalopathy 2. Transfusion-induced immune complexity (TIC) 3. Transfusion-related acute lung injury (TRALI) 4. Transfusion-associated circulatory overload (TACO) 5. Transfusion-related hemolysis 6. Transfusion-related immunomodulation 7. Transfusion fever 8. Hemosiderinuria 9. Red blood cell transfusion reactions 10. Graft-versus-host disease (GVHD) 11. Acute respiratory distress syndrome (ARDS) 12. Severe allergic reaction (SAR) 13. Citrate toxicity 14. Bacterial transfusion transmitted infections (TTIs) 15. Fungal transfusion transmission 16. HIV transmission through blood transfusion 17. Hepatitis B or C transmission 18. Viral代理人 (viral载量、感染标志物) 19. Transfusion safety protocols 20. Blood screening and quality control.
1. Leuko-reduction 2. Blood transfusion 3. Red blood cells (RBCs) 4. Infections 5. Complications 6. Transfusion-related infections (TRIs) 7. Hemolytic transfusion reaction (HTR) 8. Platelet count 9. White blood cell (WBC) reduction 10. Transfusion threshold 11. Anticoagulation 12. Blood purity 13. Apheresis 14. Pre-transfusion screening 15. Sterile technique 16. Blood bank practices 17. Donor selection 18. Immunomodulatory strategies 19. Transfusion transmitted infections (TTIs) 20. Prophylactic antibiotics.
1. Localization 2. Pin1 3. Arabidopsis embryo 4. VPS9a 5. Functional requirement 6. Protein trafficking 7. Endosomal sorting complex required for transport (ESCRT) 8. Membrane trafficking pathways 9. Signal transduction 10. Signaling cascade 11. Gene expression regulation 12. Subcellular compartmentalization 13. Traffickingcompetent proteins 14. VPS9A function 15. Genetic knockouts 16. Phenotypic analysis 17. Plant development 18. Cellular localization studies 19. Arabidopsis genetics 20. Molecular biology techniques.
1. Localization 2. Pin1 3. Arabidopsis 4. Roots 5. VPS9A 6. Functional requirement 7. Protein sorting 8. Endosomal trafficking 9. Plant biology 10. Membrane trafficking 11. Signal transduction 12. Plant vacuoles 13. Golgi apparatus 14. Atypical protein高等 15. Nondependency on VPS9A 16. Genetic analysis 17. Subcellular compartmentation 18. Plant genetics 19. Membrane-bound proteins 20. Epigenetics in root development.
1. Mir7a 2. Low expression 3. Repression 4. Target genes 5. Biological function 6. Ovaries 7. Gene regulation 8. miRNA (microRNA) 9. Epigenetic control 10. messenger RNA decay 11. Transcriptional silencing 12. Gene expression profiling 13. Ovarian tissue 14. Developmental processes 15. Fertility 16. Endocrine signaling 17. Cell differentiation 18. Stem cell biology 19. Ovarian cancer 20. Gene therapy targeting Mir7a.
1. MicroRNA (miR7a) 2. Low expression 3. Testis biology 4. Gene regulation 5. Transcriptional control 6. Epigenetics 7. Development 8. Spermatogenesis 9. Male reproductive system 10. Fetal sex determination 11. Andrology 12. Hormonal balance 13. Cell differentiation 14. Cancer susceptibility 15. Infertility 16. Testicular dysfunction 17. Gene target analysis 18. miR7a function 19. messenger RNA (mRNA) stability 20. Protein interaction 21. Stem cell biology 22. DNA methylation 23. chromatin remodeling 24. RNA interference (RNAi) 25. Genomics in testes 26. Tissue-specific expression 27. Environmental effects on mir7a levels.
1. Nucleosome occupancy 2. Low occupancy 3. DNA methylation 4. Methylation levels 5. Correlation 6. Cross-species analysis 7. Epigenetic regulation 8. Histone modification 9. Genomic chromatin structure 10. Chromatin accessibility 11. Methylation marks 12. Genomic regions 13. Transcriptional silencing 14. CpG islands 15. Non-coding DNA 16. Gene expression 17. Histone H3 lysine 4 (H3K4) 18. Histone H3 lysine 27 (H3K27) 19. Histone H3 lysine 36 (H3K36) 20. Histone acetylation 21. DNA methylation patterns 22. Evolutionary conservation 23. Epigenetic profiling 24. Transcriptomic studies 25. Functional implications.
1. Lupus 2. Prone mice 3. Curliproducing bacteria 4. Autoantibody titers 5. Comparative study 6. Experimental model 7. Infection 8. Control group 9. Immunoglobulin production 10. Autoimmune response 11. Mouse genetics 12. Bacterial infection and lupus 13. Chronic inflammation 14. Anticardiolipin antibodies 15. Antic瑞特染色体抗体 (anti-Ro/SSA) 16. Anticitrullinated protein antibodies (ACPA) 17. Antineutrophil cytoplasmic antibodies (ANCA) 18. Systemic lupus erythematosus (SLE) 19. Antibody profiling 20. Experimental autoimmune encephalitis (EAE)
1. Ly49q 2. Neutrophil migration 3. Inflammation 4. Organizational function 5. Membrane rafts 6. Regulation 7. Integrin signaling 8. Adhesion molecules 9. Chemotaxis 10. Phagocytosis 11. Immune response 12. Cytokine production 13. Activation 14. Extracellular matrix interaction 15. Transmembrane proteins 16. Endocytic pathways 17. Actin cytoskeleton 18. Microtubule-dependent movement 19. Signal transduction 20. Membrane microdomains.
1. Ly6C expression 2. Monocytes 3. Inflammatory capacity 4. Phenotypic differentiation 5. Ly6C hi cells 6. Ly6C lo cells 7. Cytokine production 8. Pro-inflammatory markers 9. Anti-inflammatory response 10. Macrophage function 11. Immune response 12. Monocyte subset 13. Regulatory T-cells 14. Tissue inflammation 15. Monocyte activation 16. Monocyte subsets and function 17. Immunoregulation 18. Inflammation vs. resolution 19. Monocyte subset comparison 20. Chronic inflammation.
1. Ly6C expression 2. Monocyte subsets 3. Inflammatory capacity 4. Ly6C hi cells 5. Ly6C lo cells 6. Cytokine production 7. Immune response 8. Macrophage function 9. Pro-inflammatory molecules 10. Anti-inflammatory properties 11. Monocyte activation 12. Regulatory T-cells 13. Chronic inflammation 14. Inflammatory disease 15. Immunostasis 16. Monocyte differentiation 17. Tissue homeostasis 18. Monocyte marker 19. Monocyte function test 20. Inflammatory cytokine profile.
1. Lymphadenopathy 2. Knockin mice 3. Shp2 (Src homologous protein 2) 4. MAPK (Mitogen-activated protein kinase) pathway 5. Gene mutation 6. Pathological enlargement of lymph nodes 7. Genetic engineering 8. Mouse model 9. Signal transduction 10. Protein dysfunction 11. Tyrosine kinase activation 12. Cancer susceptibility 13. Inflammation 14. Mouse genetics 15. Signal transducer and activator of transcription (STAT) pathway 16. Mechanistic study 17. Mouse knockouts 18. Cellular response 19. Tumor biology 20. Immunodeficiency.
1. Macrolides 2. Myocardial infarction 3. Protective effect 4. Inhibition 5. Antimicrobial action 6. Cardiac protection 7. Heart attack 8. Myocardial ischemia 9. Cardiovascular disease 10. No beneficial effect 11. Drug interaction 12. Myocardial damage 13. Anti-inflammatory agents 14. Lipid-lowering drugs 15. Contraindication 16. Myocardial reperfusion 17. Cardiac risk 18. Myocarditis 19. Preventive therapy 20. Clinical trial findings
1. Macrolide antibiotics 2. Myocardial infarction (MI) 3. Cardiac protection 4. Heart attack prevention 5. Inflammation reduction 6. Blood clot prevention 7. Staphylococcus aureus infection 8. Chlamydophila pneumoniae 9. Streptococcus pneumoniae 10. Chronic obstructive pulmonary disease (COPD) 11. Valvular heart disease 12. Atherosclerosis mitigation 13. Myocarditis prevention 14. Inflammatory biomarkers 15. Risk reduction 16. Cardiovascular health 17. Clinical trials 18. Drug therapy 19. Lifestyle modification 20. Drug-induced cardiotoxicity avoidance
1. Macropinocytosis 2. Cell supply 3. Amino acids 4. Intracellular uptake 5. Protein metabolism 6. Endocytosis 7. Membrane vesicles 8. Nutrient transport 9. Metabolic nutrition 10. Cellular nutrition 11. Endosomal pathway 12. Phagocytosis 13. Phagocytic cells 14. Primary cilium sensing 15. Receptor-mediated endocytosis 16. Cytosolic digestion 17. Tissue growth and repair 18. Protein homeostasis 19. Extracellular matrix turnover 20. Immune cell activation.
1. Post-translational modification 2. Lysine residues 3. Acetylation 4. Human cells 5. Proteins 6. Protein modification 7. Histone acetylation 8. Non-enzymatic protein modification 9. Protein turnover 10. Cellular signaling 11. Epigenetics 12. Protein function 13. Ubiquitination 14. Phosphorylation 15. Glycosylation 16. Methylation 17. Tyrosination 18. Hydroxylation 19. SUMOylation 20. Acetyllysine recognition 21. Protein stability 22. Cellular localization 23. Cellular metabolism 24. Regulatory networks 25. Transcriptional regulation
1. Mathematical modeling 2. Artemisinin-based combination therapy (ACT) 3. Nongametocytocidal drugs 4. Malaria transmission 5. Dramatic reduction 6. Disease control 7. Antimalarial treatment 8. Drug efficacy 9. Parasite elimination 10. Transmission dynamics 11. Drug resistance prevention 12. Vector control 13. Clinical trials 14. Malaria elimination strategies 15. Population pharmacokinetics 16. Epidemiological forecasting 17. Treatment guidelines 18. Public health intervention 19. Malaria surveillance 20. Prognostic modeling.
1. Mercaptopurine 2. Anabolism 3. Inactive metabolite 4. Methylmercaptopurine 5. Thiopurine methyltransferase (TPMT) 6. Drug metabolism 7. Enzymatic conversion 8. TPMT activity 9. Genetic variability 10. Pharmacogenetics 11. Drug response prediction 12. Metabolic profiling 13. Toxicity assessment 14. Drug interactions 15. Pharmacokinetics 16. Therapeutic monitoring 17. Drug dosage adjustment 18. Pharmacogenomics 19. Clinical practice guidelines 20. Patient risk stratification
1. Metastatic colorectal cancer 2. Single agent fluoropyrimidines 3. Efficacy reduction 4. Oxaliplatin-based chemotherapy 5. Elderly patients 6. Chemotherapy comparison 7. Clinical trial or study 8. Treatment outcome 9. Quality of life decline 10. Anti-cancer therapy 11. Toxicity assessment 12. Fluoropyrimidine efficacy 13. Oxaliplatin effectiveness 14. Age-related effectiveness 15. Age-adjusted treatment 16.老年CRC (colorectal cancer in the elderly) 17. Efficacy and safety in elderly population 18. Sequential vs. combination therapy 19. Age-dependent response to treatment 20. Colorectal cancer management in older adults.
1. Mice 2. Defective DNA polymerase I (PoliI) 3. Deoxyribonucleic acid (DNA) 4. Polymerase I 5. Increased sensitivity 6. Ionizing radiation (IR) 7. Radiation sensitivity 8. Genetic mutation 9. DNA repair mechanisms 10. DNA damage response 11. Radiosensitivity assay 12. Mutagenesis studies 13. DNA polymerase function 14. DNA base错配 15. DNA double-strand breaks 16. DNA cross-linking 17. Radiation-induced toxicity 18. Genotoxicity 19. Apoptosis 20. Carcinogenesis.
1. Mice 2. Interferon 3. Interferon receptor deficiency 4. Experimental autoimmune myocarditis (EAM) 5. Resistance 6. Immune tolerance 7. Autoimmune inflammation 8. Myocardial inflammation 9. Innate immune response 10. Adaptive immunity 11. IFN-α/β 12. IFN-γ 13. Regulatory T cells (Tregs) 14. CD8+ T cells 15. B cells 16. Cytokines 17. Genetic modification 18. Murine models 19. Cardiac dysfunction 20. Myocarditis susceptibility.
1. Mice 2. IFN (Interferon) 3. Receptor 4. Resistant 5. EAM (Experimental Autoimmune Myocarditis) 6. MyHC (Myosin Heavy Chain) 7. CFA (Calf Anti-Myosin) 8. Immune response 9. Inflammation 10. Autoimmunity 11. Myocardial damage 12. Genetic modification 13. Knockout mice 14. Non-responsiveness 15. EAM model 16. Myosin-specific immunity 17. Regulatory T-cells 18. T-cell tolerance 19. Immunomodulation 20. Myocardial protection.
1. Microrna 2. Neural stem cells (NSCs) 3. Differentiation 4. Proliferation 5. Dynamic homeostasis 6. Regulatory mechanism 7. Gene expression 8. Stem cell biology 9. Cell fate determination 10. Neural progenitor cells 11. Neural tissue development 12. Epigenetic control 13. miRNA function 14. Stem cell niche 15. Stem cell self-renewal 16. Cell cycle regulation 17. Transcriptional regulation 18. Stem cell signaling pathways 19. Cell cycle arrest 20. Neural development disorders 21. miRNA-targeted genes 22. Tissue regeneration 23. Stem cell aging 24. Stem cell therapy.
1. Microarray analysis 2. Culture-amplified mixtures 3. Serotype identification 4. Poor correlation 5. Uncultured samples 6. Gene expression profiling 7. Prognostic value 8. Cultivation-dependent data 9. Culture-independent methods 10. Comparative genomics 11. Molecular diagnostics 12. Serotyping techniques 13. Hybridization efficiency 14. Assay validation 15. Microarray normalization 16. Biomarker discovery 17. Microbial diversity 18. Quantitative PCR (qPCR) 19. Shotgun sequencing 20. Functional annotation 21. Meta-genomics 22. Culture recovery rate 23. Microarray technology 24. Microarray platform 25. Cross-platform comparison.
1. Mitochondria 2. Apoptosis 3. Uninvolved 4. Cellular death 5. Programmed necrosis 6. Caspases 7. Bcl-2 family 8. Mitochondrial outer membrane 9. Mitochondrial inner membrane 10. Mitochondria-dependent 11. Mitochondria-independent 12. Mitochondria release 13. Cytochrome c 14. Endoplasmic reticulum stress 15. Autophagy 16. Necroptosis 17. Antimycin A sensitivity test 18. Caspase-3 activation 19. Mitochondrial dysfunction 20. Apoptotic signaling pathway
1. Epigenome modification 2. Brain aging 3. Neurogenesis 4. Genetic regulation 5. DNA methylation 6. Histone modifications 7. Non-coding RNAs (ncRNAs) 8. Chromatin remodeling 9. Telomere lengthening 10. Gene expression changes 11. Epigenetic clock 12. Senescence-related genes 13. Neuroplasticity 14. Aging-related pathways 15. Brain development 16. Stem cell function 17. Cytosine DNA base modification 18. imprinting 19. DNA accessibility 20. Aging-related diseases 21. Neurodegeneration 22. Epigenetic biomarkers 23. Telomere dynamics 24. Epigenetic therapy 25. Aging and cognition.
1. Monoclonal antibodies 2. N-cadherin 3. Metastasis prevention 4. Targeted therapy 5. Cancer invasion 6. Cell adhesion inhibition 7. Epithelial-to-mesenchymal transition (EMT) 8. Cancer stem cells 9. Anti-cancer drugs 10. Inhibitory effect 11. Tumor suppressor 12. Cancer recurrence 13. Cancer biomarker 14. Immunotherapy 15. Clinical trials 16. N-cadherin antagonist 17. Cancer stem cell marker 18. Anti-metastatic drug development 19. Multidisciplinary approach 20. Cancer diagnosis
1. Okazaki fragments 2. Termination events 3. Sequence specificity 4. DNA replication 5. Primer extension 6. DNA polymerase III 7. DNA polymerase II 8. Primer recognition 9. Primer/template binding 10. Proofreading 11. Mismatch repair 12. Primase activity 13. Polynucleotide chain elongation 14. Okazaki junction 15. DNA ligation 16. DNA sequencing 17. Genetic information 18. Base pairing rules 19. Template switching 20. DNA mismatch analysis.
1. Mutant mice 2. SVCT2 deficiency 3. Ascorbic acid (Vitamin C) 4. Increased levels 5. Brain 6. Adrenals 7. Metabolic regulation 8. Bioavailability 9. Vitamin C transport 10. Genetic manipulation 11. Cellular metabolism 12. Tissue distribution 13. Nutrient homeostasis 14. Mouse model 15. Vitamin C supplementation 16. Hypovitaminosis 17. Enzyme function 18. Genetic engineering 19. Biochemical analysis 20. Tissue-specific effects.
1. Mutations 2. G beta protein (GNB2) 3. Cancer 4. Loss of interaction 5. G alpha subunits 6. Concomitant activation 7. Akt pathway 8. Signal transduction 9. Protein dysfunction 10. Oncogenic changes 11. beta-catenin signaling 12. Gain-of-function 13. Pathway deregulation 14. Cell proliferation 15. Survival enhancement 16. Tumor growth 17. Metastasis 18. G protein-coupled receptors (GPCRs) 19. Membrane receptor dysregulation 20. Targeted therapies.
1. Transcription start site (TSS) 2. N-terminal cleavage 3. RNA processing 4. Initiation factor 5. Elongation factor 6. 5' cap cleavage 7. Pol II initiation 8. Capping machinery 9. RNA polymerase II 10. Enhancer elements 11. Chromatin accessibility 12. Promoter recognition 13. Start-site detection 14. Precise mapping 15. Gene expression analysis 16. Transcriptomics 17. Cleavage-specific markers 18. RNA sequencing (RNA-seq) 19.剪接体 20. Splicing regulation.
1. N-terminal cleavage 2. Transcription start site (TSS) identification 3. Failure in TSS detection 4. Protein processing 5. Pre-mRNA splicing 6. RNA-cleavage events 7. Alternative splicing 8. Cleavage specificity 9. 3' end processing 10. Capping and polyadenylation 11. Non-canonical cleavage 12. Exon skipping 13. RNA sequencing (RNA-seq) 14. Chromatin immunoprecipitation (ChIP-seq) 15. RNA剪接mapper 16. Transcriptome analysis 17. TSS prediction algorithms 18. Gene expression profiling 19. Cleavage bias 20. Regulatory element disruption.
1. N348I mutation 2. Zidovudine (AZT) 3. Resistance 4. Drug resistance 5. HIV therapy 6. HIV mutation 7. Reverse transcriptase inhibitor 8. Atriplenavir 9. Tenofovir 10. Nucleoside reverse transcriptase inhibitors (NRTIs) 11. HIV protease inhibitors 12. AIDS treatment 13. Genetic resistance 14. Viral evolution 15. Drug selectivity 16. Antiretroviral resistance 17. HCV (hepatitis C virus) analogues 18. AZT resistance mechanism 19. Drug pharmacokinetics 20. Drug monitoring in HIV patients.
1. NF2 (Neurofibromin 2) 2. Merlin 3. Phosphorylation 4. Subsequent cytoplasmic sequestration 5. Yap (YAP1/TAZ) 6. Drosophila 7. Activation 8. LATS1/2 kinases 9. Signal transduction 10. Cell regulation 11. Protein phosphorylation cascade 12. Cytoskeleton organization 13. Tumor suppressor mechanism 14. Hippo pathway 15. Growth control 16. Cytosolic localization 17. Nuclear-cytosolic balance 18. Gene expression modulation 19. Developmental control 20. Cell fate determination.
1. NF2 (Neurofibromin 2) 2. Merlin 3. Phosphorylation 4. Cytoplasmic sequestration 5. Drosophila 6. Yeast artificial chromosome (YAC) or transgenic fly lines 7. Yap (Yes-associated protein) 8. Cell signaling pathway 9. Protein-protein interaction 10. Tumor suppressor function 11. Membrane ruffles 12. Cytoskeleton regulation 13. Cell growth control 14. Nuclear-cytoplasmic transport 15. Hippo signaling pathway 16. Hippo-YAP complex 17. Cell cycle arrest 18. Tissue development 19. Genetic mutation studies 20. Loss-of-function analysis.
1. NFAT4 (Nuclear Factor of Activated T-cells 4) 2. Activation 3. IP3R (Inositol 1,4,5-trisphosphate receptor) 4. Calcium (Ca2+) 5. Mobilization 6. IP3 signaling pathway 7. Endoplasmic reticulum calcium release 8. Calmodulin binding protein 9. Cytosolic calcium stores 10. Calcium homeostasis 11. Calcium-induced transcription 12. T-cell biology 13. Hormone-sensitive phospholipase C (PLC) 14. Phosphorylation events 15. Calcineurin-dependent activation 16. Calcium-responsive genes 17. Intracellular calcium release channel 18. Signal transduction 19. Immunological response 20. Transcription factor regulation.
1. NADPH oxidase 2 (NOX2) 2. Independent pathways 3. Peroxynitrite production 4. Nitrogen intermediates 5. Reactive oxygen species (ROS) 6. Superoxide anion (O2) 7. Nitric oxide (NO) 8. Nitrogen dioxide (NO2) 9. Endogenous generation 10. Enzymatic reactions 11. Peroxynitrate synthase 12. Nitric oxide dioxygenase (NAD(P)H oxidases) 13. Phagocytic cells 14. Macrophages 15. Mitochondria 16. Extracellular matrix 17. Extracellular reactive nitrogen species (eNOS) 18. Peroxylation 19. Oxidative stress 20. Signal transduction
1. Nr5a2 2. Endometrial tissue development 3. Gene expression 4. Regulatory role 5. Fetal biology 6. Reproductive hormones 7. Cell differentiation 8. Epigenetics 9. Wnt/β-catenin signaling 10. Estrogen receptor 11. Progesterone action 12. Endometrial gland formation 13. Stromal cells 14. Cytokine production 15. Tissue proliferation 16. Proliferation Arrest 17. Implantation and pregnancy 18. Gene therapy 19. Cellular metabolism 20. Disease association (e.g., endometriosis, infertility)
1. Nanoparticles 2. Targeting specificity 3. Aptamers 4. Cell types 5. Ligand engineering 6. Lipid nanoparticles (LNPs) 7. Specific binding 8. Affinity recognition 9. Cell membrane interaction 10. Drug delivery 11. Theranostics 12. Bioconjugation 13. Biomolecular recognition 14. Cell labeling 15. Diagnostic applications 16. Therapeutic targeting 17. Functionalized LNPs 18. Nanocarriers 19. Surface modification 20. Biomedical research.
1. Neutrophil extracellular traps (NETs) 2. Anca stimulation 3. Activated neutrophils 4. Phagocytosis 5. Complement cascade 6. Cytokine release 7. Innate immune response 8. Microbial capture 9. Web-like structures 10. DNA release 11. Interferon-gamma (IFN-γ) 12. C-reactive protein (CRP) 13. Lysosomal damage 14. Host defense mechanism 15. Zymosan particles 16. NETosis 17. Extracellular matrix degradation 18. Granulocyte-macrophage colony-stimulating factor (GM-CSF) 19. Macrophage activation 20. Pathogen elimination.
1. Tuberculosis 2. New drugs 3. Penetration 4. Necrotic tissue 5. Lesion 6. High concentrations 7. Drug efficacy 8. Drug resistance 9. Mycobacterium tuberculosis 10. Anti-tubercular therapy (ATT) 11. Targeted drug delivery 12. Pulmonary infection 13. Tissue healing 14. Drug interaction 15. Cytotoxic necrosis 16. Drug metabolism 17. Tuberculoma 18. Granulomas 19. Drug penetration enhancement 20. Tuberculous abscess
1. Non-invasive ventilation (NIV) 2. Inadequate response 3. Conventional treatment 4.weaning from NIV 5. Prolonged NIV usage 6. Ventilator dependence 7. Respiratory failure 8. Patient improvement 9. Alternative therapies 10. Clinical assessment 11. Medical decision-making 12. Discontinuation guidelines 13. Progression to intubation 14. Intensive care unit (ICU) intervention 15. Oxygen therapy optimization 16. Pulmonary rehabilitation 17. Acute respiratory distress syndrome (ARDS) 18. Chronic obstructive pulmonary disease (COPD) 19. Pneumonia 20. Sleep apnea management.
1. Runx1 2. Normal expression 3. Tumor promotion 4. Oncogenic activity 5. Cancerogenesis 6. Cellular transformation 7. Pro-inflammatory cytokines 8. Metastasis 9. Angiogenesis 10. Cell proliferation 11. Immune evasion 12. Gene mutation 13. Loss-of-function studies 14. Gain-of-function experiments 15. Targeted therapy 16. Signaling pathways 17. Wnt/β-catenin pathway 18. Runx1 oncogene 19. Cancer stem cells 20. Prostate cancer 21. Breast cancer 22. Leukemia 23. Sarcoma 24. Pancreatic cancer 25. Clinical implications.
1. Overweight 2. Body mass index (BMI) 3. Health risks 4. Chronic diseases 5. Diabetes 6. Heart disease 7. High blood pressure 8. Sleep apnea 9. Respiratory issues 10. Mental health problems 11. Depression 12. Low self-esteem 13. Inactivity 14. Sedentary lifestyle 15. Poor nutrition 16. Accessibility to healthcare 17. Social stigma 18. Physical limitations 19. Reduced mobility 20. Quality of life assessment 21. Fitness and well-being 22. Weight management 23.Obesity prevention 24. Health education 25. Active living initiatives.
1. Environmental determinism 2. Lifestyle choices 3. Food availability 4. Access to healthy options 5. Socioeconomic status 6. Physical environment 7. Urban planning 8. Food marketing 9. Genetic predisposition 10. Cultural habits 11. Lack of physical activity 12. Obesogenic environment 13. Overconsumption 14. Caloric intake 15. Education and awareness 16. Sedentary lifestyle 17. Environmental toxins 18. Sleep patterns 19. Stress 20. Food insecurity
1. Ribosomal occupancy 2. Incrnas (internal ribosomal entry sites) 3. Functional peptides 4. Non-functional protein synthesis 5. Translation initiation 6. Post-transcriptional modifications 7. frameshifting 8. Alternative splicing 9. Missed cleavage 10. IRES elements 11. Suboptimal codon usage 12. Protein折叠异常 13. Non-productive elongation 14. Regulatory mechanisms 15. RNA-protein interactions 16. mRNA stability 17. Cellular localization 18. Protein trafficking 19. Cerebral palsy, muscular dystrophy, and other diseases 20. Protein misfolding disorders
1. Ribosome occupancy 2. IncRNAs (intergenic non-coding RNAs) 3. Mirror RNAs 4. 5' UTRs (untranslated regions) 5. Gene expression 6. Translational regulation 7. mRNA processing 8. Transcriptomics 9. RNA-seq analysis 10. Regulatory elements 11. Promoters 12. Enhancers 13. Silencers 14. ICR (intron downstream region) 15. Exonic-intronic boundaries 16. Non-coding function 17. Alternative splicing 18. Translational control 19. Gene expression profiling 20. Computational biology.
1. Omnivores 2. Trimethylamine N oxide (TMAO) 3. Dietary intake 4. Carnitine 5. Vegetarians 6. Comparative study 7. Nutrition 8. Metabolism 9. Digestive system 10. L-carnitine 11. Meat consumption 12. Animal products 13. Plant-based diet 14. Choline 15. Lipid metabolism 16. Bioavailability 17. TMAO production 18. Health effects 19. Food choice 20. Carnitine metabolism in omnivores vs vegetarians.
1. Stress resistance 2. Cellular differentiation 3. Spore formation 4. Survival rate 5. Minority cells 6. Metabolic adaptation 7. Genetic stability 8. Bacterial persistence 9. Fungal sporulation 10. Epigenetic changes 11. Stress response mechanisms 12. Cell survival genes 13. Stress-tolerant spores 14. Antioxidant mechanisms 15. DNA damage repair 16. Quiescence and dormancy 17. Stress-induced selection 18. Epithelial-to-mesenchymal transition (EMT) 19. Cell cycle arrest 20. Cellular senescence.
1. PD (pro-inflammatory disease) 2. Triggering 3. Monocytes 4. IL-10 (interleukin-10) 5. Production 6. Immune response 7. Inflammation 8. Regulatory T-cells 9. Anti-inflammatory effect 10. Monocyte activation 11. Cytokine release 12. Chronic inflammation 13. Immunomodulation 14. Pathway analysis 15. Clinical trials 16. Biomarkers 17. Immunosuppression 18. Therapeutic target 19. Cell signaling 20. Monocytic dysfunction
1. Pdpn (Positive Dendritic Cell Polarization Neutrophil) 2. Efficient motility 3. Stromal surfaces 4. C-type lectin receptor (CLR) 5. Actin cytoskeleton 6. Dendritic cells (DCs) 7. Activation 8. Cell rearrangement 9. Adhesion and migration 10. Immune response 11. Integrin signaling 12. Actin polymerization 13. Filamentous actin (F-actin) 14. Membrane ruffling 15. Transmembrane protein 16. Cytoskeletal dynamics 17. Tissue repair 18. Inflammation regulation 19. Microphage activation 20. Phagocytosis.
1. PGE2 (Prostaglandin E2) 2. Intestinal Tumor Growth 3. Altered Expression 4. Tumor Suppressor Genes 5. DNA Repair Genes 6. Molecular Mechanism 7. Cancerogenesis 8. Pro-inflammatory mediator 9. Epigenetic regulation 10. Gene dysregulation 11. Pathway activation 12. Signal transduction 13. Cell cycle control 14. Genetic instability 15. Oncogenic potential 16. Cancers of the colon/rectum 17. Targeted therapy 18. Preclinical studies 19. Clinical implications 20. Gene therapy.
1. pkg (proteins or gene) 2. la (specific protein or gene product) 3. expression 4. pain hypersensitivity 5. pgk la (gene or protein isoform) 6. knockout mice 7. genetic manipulation 8. molecular biology 9. cellular function 10. neurotransmission 11. inflammation 12. nociceptors 13. sensory perception 14. ion channels 15. calcium signaling 16. pain pathways 17. gene knockout models 18. functional analysis 19. gene-disease association 20. pain-related disorders.
1. Peroxisome proliferator-activated receptors (PPARs) 2. RXR (Retinoid X receptor) 3. Ligands 4. Activation 5. Inhibition 6. PPAR agonists 7. PPAR antagonists 8. Thiazolidinediones (TZDs) 9. Fatty acid ligands 10. Retinoids 11. Antidiabetic drugs 12. Anti-inflammatory agents 13. Lipid metabolism 14. Gene expression regulation 15. Cell signaling 16. Tissue differentiation 17. Health effects 18. Drug development 19. Therapeutic targets 20. Drug action on RXRs.
1. Peroxisome proliferator-activated receptors (PPARs) 2. Ligands 3. Activation 4. PPAR receptor binding 5. Thiazolidinediones (TZDs) 6. Fatty acid transport agonists 7. Antidiabetic drugs 8. Retinoid X receptors (RXRs) 9. Ligand-activated transcription 10. RXR-PPAR cooperation 11. Peroxisome biogenesis 12. Gene expression regulation 13. Liver function modulation 14. Insulin sensitivity 15. Adipocyte differentiation 16. Lipid metabolism 17. Peroxisome proliferator response elements (PPREs) 18. Drug development 19. Endocrine signaling 20. Peroxisome activation.
1. Cognitive function 2. Physical activity 3. Six-month intervention 4. Exercise routine 5. Fitness program 6. Brain health 7. Neuroplasticity 8. Mental acuity 9. Memory enhancement 10. Attention span 11. Executive function 12. Learning capacity 13. Brain stimulation 14. Neurochemical changes 15. Neurotrophic factors 16. Aging and cognition 17. Cognitive decline prevention 18. Lifestyle modification 19. Physical exercise benefits 20. Cognitive performance improvement
1. HIV 2. Stable partnership 3. Progression to AIDS 4. Patient demographics 5. Sexual health 6. Viral load 7. CD4 count 8. Immunocompetence 9. Antiretroviral therapy (ART) 10. AIDS diagnosis 11. Risk factors 12. Behavioral health 13. HIV transmission 14. Time to AIDS 15. HIV seroconversion 16. Prevention and control 17.一对性伴侣 18. Serostatus 19. Partner concurrency 20. HIV/AIDS prevalence in relationships.
1. Peroxynitrite 2. Nitration 3. TCR (T cell receptor) 4. CD8 (CD8+ T cells) 5. Nitric oxide metabolism 6. Oxidative stress 7. Immune response 8. Protein modification 9. Nitrative damage 10. Activation of T cells 11. Cell signaling 12. Nitrotyrosine residues 13. Nitric oxide synthase 14. Nitrogen dioxide 15. Immunology 16. DNA modification 17. Nitration of proteins 18. T cell activation cascade 19. Peroxynitrite donors 20. Nitration of CD8+ T cell markers.
1. Pleiotropy 2. Glp-1 receptor (GLP1R) 3. Intracellular effectors 4. Cellular signaling 5. Distinct profiles 6. Mechanism of action 7. Metabolic regulation 8. Insulin sensitivity 9. Glucose homeostasis 10. Incretin hormones 11. cAMP/protein kinase A (PKA) signaling 12. Calcitonin gene-related peptide (CGRP) pathways 13. Mitogen-activated protein kinases (MAPKs) 14. Phosphatidylinositol 3-kinase (PI3K)/Akt pathway 15. AMP-activated protein kinase (AMPK) activation 16. Cellular metabolism 17. Anti-diabetic effects 18. Appetite regulation 19. Autophagy induction 20. Inflammation response.
1. Podocytes 2. Motility 3. Migration 4. Injury 5. Renal injury 6. Glomerular filtration 7. Wound healing 8. Epithelial cell movement 9. Stress response 10. Axoneme dynamics 11. Slit diaphragm function 12. Podocyte footprocesses 13. Extracellular matrix interactions 14. Actin cytoskeleton rearrangement 15. Chemotaxis 16. Mesangial cell activation 17. Diabetic nephropathy 18. Renal fibrosis 19. Inflammatory response 20. Blood filtration regulation
1. Polymeal 2. Nutrition 3. Cardiovascular health 4. Mortality reduction 5. Heart disease prevention 6. Risk factor mitigation 7. Cholesterol management 8. Blood pressure control 9. Anti-inflammatory properties 10. Antioxidants 11. Omega-3 fatty acids 12. Fiber content 13. Plant-based diet 14. Micronutrient balance 15. Cardiovascular disease prevention 16. Cardiovascular disease management 17. Lifestyle modification 18. Cardiovascular wellness 19. Nutrient density 20. Cardiovascular risk reduction strategy
1. Pretreatment 2. ARP2 3 inhibitor 3. CK-666 4. Lamellipodia formation 5. Cell signaling 6. Actin polymerization 7. Cell adhesion 8. Cell migration 9. Extracellular matrix interaction 10. Cytoskeleton dynamics 11. Epithelial cell behavior 12. Wound healing 13. Tissue repair 14. Cell protrusion 15. Filopodia development 16. Motility assays 17. In vitro experiments 18. Biological function 19. Drug screening 20. Mechanistic studies.
1. Primary cervical cancer screening 2. HPV detection 3. Longitudinal sensitivity 4. Cervical intraepithelial neoplasia (CIN) grade 2 5. Conventional cytology 6. Early detection 7. Pap smear test 8. HPV-based testing 9. Cervical precancerous lesions 10. Preventive care 11. Cervical cancer prevention 12. Regular screenings 13. HPV vaccine 14. Cervical cancer risk reduction 15. Early intervention 16. Colposcopy 17. Cervical biopsy 18. High-risk HPV types 19. Precancerous transformation 20. Early-stage detection.
1. Primary pro-inflammatory cytokines 2. Secondary pro-inflammatory mediators 3. Induction 4. Immune response 5. Inflammation 6. Cytokine signaling 7. Pro-inflammatory cascade 8. Interleukins (IL-1, IL-6, TNF-α) 9. Chemokines 10. Monocytes/macrophages 11. Neutrophils 12. Th1/Th2 differentiation 13. Tumor necrosis factor-alpha (TNF-α) 14. Interleukin-6 (IL-6) 15. Interleukin-8 (IL-8) 16. C-reactive protein (CRP) 17. Pro-resolving mediators 18. Anti-inflammatory cytokines (IL-10, IL-4, IL-13) 19. Dendritic cells 20. Regulatory T-cells (Tregs)  21. Resolution phase 22. Chronic inflammation 23. Immunosuppression 24. Inflammatory diseases 25. Pathogen recognition.
1. Growth cone 2. Protein synthesis 3. Ubiquitination 4. Higher rate 5. Cellular localization 6. Synaptic differentiation 7. Molecular trafficking 8. Signal transduction 9. Membrane protrusion 10. Cell membrane dynamics 11. Protein turnover 12. Protein modification 13. Cytosolic proteins 14. Cytoplasmic transport 15. Transcriptional regulation 16. Translation efficiency 17. Protein localization at the leading edge 18. Microtubules and actin dynamics 19. Axon guidance 20. Neural development.
1. Pseudogene 2. Ptenp1 3. Expression regulation 4. Pten (PTEN) 5. MicroRNA (miRNA) 6. Decoy mechanism 7. miRNA targeting 8. Gene silencing 9. Alternative splicing 10. Non-coding RNA 11. PTEN promoter 12. miRNA binding site 13. Epigenetic control 14. Transcriptional repression 15. Ptenp1 function 16. miRNA-mRNA interaction 17. Regulatory non-coding element 18. Ptenp1 role in cancer 19. miRNA-based therapy 20. Post-transcriptional regulation.
1. Pyridostatin 2. Telomeric region 3. G-quadruplex 4. Stability 5. Destabilization 6. Telomeres 7. DNA structure 8. Nucleic acids 9. Telomerase inhibition 10. Telomeric repeats 11. Cancer therapy 12. Gene expression regulation 13. Epigenetics 14. Telomeric dysfunction 15. Quaternary structure 16. Antisense compounds 17. Telomeric DNA 18. G4-stabilizing agents 19. Cancer biomarker 20. Telomere shortening
1. Radioiodine therapy 2. Non-toxic multinodular goitre 3. Thyroid volume reduction 4. Iodine-assisted treatment 5. Goiter management 6.自主性甲状腺功能亢进（自主性高功能甲状腺腺瘤） 7. Compensatory hyperplasia 8. Radioactive iodine uptake 9. Residual thyroid tissue 10. Functional goiter 11. Total thyroidectomy 12. Hormonal control 13. iodine scanning 14. Subtotal thyroidectomy 15. Long-term effects 16. Patient outcomes 17. Risk reduction 18. Non-surgical intervention 19. Contraindications 20. Follow-up care.
1. Rapamycin 2. Triacylglycerols 3. Fruit flies 4. Lipid metabolism 5. Fatty acid accumulation 6. Inhibitor 7. Calorie restriction 8. Diacylglycerol synthesis 9. Triglyceride levels 10. Lipid droplet reduction 11. AMP-activated protein kinase (AMPK) activation 12. Metabolic regulation 13. Sterol regulatory element-binding protein (SREBP) inhibition 14. Adipocyte differentiation 15. Fat storage 16. Insulin sensitivity 17. Lipidomics 18. Fly genetics 19. Experimental model 20. Anti-obesity effect.
1. Phosphotransfer 2. Fidelity 3. Two-component systems 4. Rapid rates 5. Kinetics 6. Signal transduction 7. Protein-protein interaction 8. Cofactor binding 9. Adenosine triphosphate (ATP) 10. Enzymatic activity 11. Genetic regulation 12. Signal integration 13. Response accuracy 14. Signal specificity 15. Feedback mechanisms 16. Signal amplification 17. Phosphorylation events 18. Conformational changes 19. Redox reactions 20. Transmembrane signaling
1. Rapid upregulation 2. Higher basal expression 3. Interferon-inducible genes 4. Granule cell neurons 5. West Nile Virus infection 6. Innate immune response 7. Antiviral defense 8. IFN (interferon) signaling 9. Gene transcription 10. Pro-inflammatory cytokines 11. Cellular survival 12. Neuroprotection 13. Antiviral mechanisms 14. Virus-induced inflammation 15. Stress response 16. Apoptosis prevention 17. Immune surveillance 18. Genetic modification 19. Gene therapy 20. Viral clearance.
1. Rapid up-regulation 2. Higher basal expression 3. Interferon-induced genes 4. Granule cell neurons 5. West Nile Virus (WNV) infection 6. Viral infection 7. Immune response 8. Innate immunity 9. Type I interferons (IFNs) 10. Gene expression profiling 11. Survival rate 12. Neurological damage 13. Neuroinflammation 14. Antiviral defense 15. Cytokine production 16. Apoptosis 17. Cell death 18. Neurotoxicity 19. Virus-host interactions 20. Neurological disease progression.
1. Recurrent mutations 2. Frequent occurrence 3. CTCF anchor sites 4. Oncogenes 5. Genetic instability 6. Chromatin remodeling 7. DNA binding protein CTCF 8. Tumor suppressor genes 9. Cancer susceptibility 10. Epigenetic changes 11. Gene regulatory regions 12. Cancer driver mutations 13. Gene-gene interactions 14. Cancer hallmark 15. Genomic instability 16. Telomeric repeats 17. CpG islands 18. Transcription factor binding 19. Oncogenic promoter regions 20. Cytokinesis checkpoint.
1. Regulatory T cells (Tregs) 2. Interleukin-2 (IL-2) 3. Reduced responsiveness 4. Autoimmune diseases 5. Type 1 diabetes 6. Immune tolerance 7. T cell dysfunction 8. CD4+ Tregs 9. IL-2 signaling 10. Immune response modulation 11. Self-tolerance 12. Autoimmunity 13. Inflammatory bowel disease (IBD) 14. Multiple sclerosis (MS) 15. Autoantibody production 16. Cytokine balance 17. T cell exhaustion 18. Regulatory environment 19. T cell-dependent diseases 20. Clinical implications 21. Immunotherapy targets 22. Indoleamine-2,3-dioxygenase (IDO) pathway 23. Th17 cell balance 24. Regulatory genetics 25. Immunosuppression.
1. Histone H2A replacement 2. H2A Z substitution 3. Gene activation regulation 4. Yeast cells 5. Nucleosome stability 6. Epigenetic modification 7. Transcriptional repression 8. Chromatin compaction 9. H2A.Z isomerase 10. Nucleosome reorganization 11. Histone code 12. Genomic imprinting 13. DNA accessibility 14. Transcriptional silencing 15. Histone variant function 16. Chromatin landscape 17. Epigenetic mark H2A.Z 18. Yeast genetics 19. Epigenetics and development 20. Cellular differentiation.
1. Ribosomopathies 2. Low specificity 3. Cell and tissue specificity 4. Pathology 5. Genetic disorders 6. Molecular defects 7. Enzymatic abnormalities 8. Mitochondrial involvement 9. Nucleolar dysregulation 10. Cytoskeletal alterations 11. Cellular transport disorders 12. Protein synthesis disruption 13. Organ-specific symptoms 14. Multi-systemic involvement 15. Heterogeneity 16. Hematological manifestations 17. Neurological complications 18. Renal dysfunction 19. Cardiac issues 20. Respiratory problems 21. Skeletal myopathy 22. Liver damage 23. Inborn errors of metabolism 24. Genetic testing 25. Diagnosis and classification 26. Treatment options 27. Prognosis in ribosomopathies 28. Targeted therapies 29. Clinical spectrum 30. Genetic counseling.
1. S-nitrosylation 2. Gapdh (glyceraldehyde-3-phosphate dehydrogenase) 3. Physiological transnitrosylation 4. Histone deacetylases (HDACs) 5. Protein modification 6. Nitrosylation reactions 7. Redox signaling 8. NOS (nitric oxide synthase) 9. Enzymatic activity 10. Post-translational modification 11. Histone modification 12. Acetylation/deacetylation 13. Chromatin regulation 14. DNA accessibility 15. Cellular homeostasis 16. Cancer biology 17. Neurobiology 18. Developmental biology 19. Gene expression 20. Tissue-specific effects
1. Sildenafil 2. Erectile dysfunction 3. Sexual dysfunction 4. SSRI antidepressants 5. Erectile improvement 6. Sexual performance 7. Penile function 8. Sexual satisfaction 9. Erectile response 10. Erectile reliability 11.SSRI side effect 12. Antidepressant-related ED 13. Erectile enhancement 14. Sexual interest 15. Sexual desire 16. Sexual arousal 17. PDE5 inhibitors 18. Erectile dysfunction treatment 19. Sexual activity 20. Sexual well-being.
1. Bcl2 silencing 2. Tumor maintenance 3. Tumor progression 4. Cancer biology 5. Apoptosis regulation 6. Anti-proliferative effects 7. Cell survival 8. Oncogenetic pathways 9. Anti-cancer therapy 10.不死基因(Bcl-2) 11. Survival protein 12. Tumor suppressor mechanism 13. Chronic inflammation 14. Chemotherapy sensitivity 15. Targeted therapies 16. Bcl-2 family proteins 17. Survival of cancer cells 18. Metastasis prevention 19. Genetic mutations 20. Cellular immortality.
1. SMC5/6 complex 2. Engagement drives 3. ATP-dependent remodeling 4. SUMO E3 ligase 5. MMS21 protein 6. Activation process 7. Ubiquitin ligase system 8. Protein-protein interaction 9. Cellular signaling 10. DNA damage response 11. DNA repair mechanism 12. chromatin modification 13. SUMOylation 14. E3 ubiquitin ligase MMS21 15. Cytoskeleton organization 16. Cellular cycle regulation 17. Telomere maintenance 18. DNA integrity checkpoint 19. Energy source (ATP) 20. Cellular homeostasis.
1. Statins 2. Blood cholesterol 3. Hypercholesterolemia 4. Lipid lowering 5. HMG-CoA reductase inhibitors 6. Cholesterol synthesis inhibition 7. LDL (low-density lipoprotein) 8. HDL (high-density lipoprotein) 9. Triglyceride levels 10. Atherosclerosis prevention 11. Cardiovascular disease 12. Heart health 13. Primary prevention 14. Secondary prevention 15. Atorvastatin 16. Simvastatin 17. Rosuvastatin 18. Zocor 19. Crestor 20. Lescol
1. Statins 2. Blood cholesterol 3. Hypercholesterolemia 4. LDL (low-density lipoprotein) 5. HDL (high-density lipoprotein) 6. Cholesterol levels 7. Cardiovascular health 8. Atherosclerosis 9. Risk reduction 10. Statin therapy 11. Lipid-lowering medication 12. Statin side effects 13. Total cholesterol 14. HDL-C and LDL-C ratios 15. Fatty acids 16. Cholesterol metabolism 17. Primary prevention 18. Secondary prevention 19. Risk factor management 20. Diet and statins.
1. Stroke patients 2. Prior use of direct oral anticoagulants (DOACs) 3. Lower risk 4. In-hospital mortality 5. Direct oral anticoagulants (specific DOACs like apixaban, dabigatran, rivaroxaban, or edoxaban) 6. Warfarin 7. Anticoagulation therapy 8. Prophylaxis 9. Cardiovascular events 10. Stroke prevention 11. Anticoagulant effectiveness 12. Risk comparison 13. Randomized controlled trials 14. Clinical trials 15. Health outcomes 16. Thromboembolic stroke 17. Haemorrhagic stroke 18. Anticoagulant bleeding 19. Anticoagulant management 20. Stroke care.
1. Subcutaneous fat 2. Browning processes 3. Cold exposure 4. Adipose tissue browning 5. Thermogenesis 6. Lipid oxidation 7. Ucp1 expression 8. Non-shivering thermogenesis 9. Cold-induced fat metabolism 10. Brown adipose tissue (BAT) 11. Thermoregulation 12. Cold tolerance 13. Energy storage 14. Hypothermia protection 15. Cold-induced thermogenesis genes 16. Cold-stimulated lipolysis 17. beige adipocytes 18. Cold adaptation 19. Thermogenic capacity 20. Cold exposure effects on fat.
1. Optimal nutrition 2. Suboptimal diet 3. Chronic diseases 4. Predictive factors 5. Nutritional deficiencies 6. Malnutrition 7. Health outcomes 8. Chronic illness 9. Disease risk 10. Diet quality 11. Micronutrients 12. Macronutrients 13. Dietary patterns 14. Nutrient adequacy 15. Nutrition science 16. Epidemiology 17. Lifestyle and nutrition 18. Environmental nutrition 19. Nutritional assessment 20. Preventive medicine.
1. Synaptic activity 2. Local release 3. Brain-derived neurotrophic factor (BDNF) 4. Postsynaptic dendrites 5. Neurotransmission 6. Plasticity 7. Axonal signaling 8. Dendritic spine 9. Synaptic vesicles 10. Neurotrophic growth factors 11. Activity-dependent release 12. Calcium ions 13. Protein synthesis 14. Neuroprotection 15. Neurogenesis 16. Dendritic spine remodeling 17. Synaptic strengthening 18. Hebbian learning 19. Long-term potentiation (LTP) 20. Depression-related mechanisms
1. T regulatory (Treg) cells 2. TTregs (tumor-specific Tregs) 3. V8 gene deficiency 4. Suppression 5. Pathogenic T cell responses 6. Active inflammation 7. Immune regulation 8. Regulatory T cell function 9. Cytokine production 10. TGF-β signaling 11. CD25 expression 12. FoxP3+ Tregs 13. Th17 cell inhibition 14. Inflammatory bowel disease 15. Autoimmune disorders 16. T cell tolerance 17. Immunomodulation 18. Regulatory T cell activation 19. Chronic inflammation 20. T cell exhaustion.
1. TCR (T cell receptor) 2. CD3 3. Microdomains 4. Immunologic synapse 5. Activation 6. T cells 7. Signal transduction 8. Intracellular trafficking 9. T cell activation cascade 10. Integrins 11. Z-discs 12. Actin rearrangement 13. Cytoskeleton organization 14. Calcium signaling 15. T cell receptor clustering 16. Co-stimulatory molecules 17. Ligand recognition 18. Central immune complex 19. Primary lymphoid organs 20. Chronic viral infections.
1. Tumor suppressor 2. TNFAIP3 3. Glioblastoma 4. Genetic mutation 5. Oncogenetic function 6. Cellular regulation 7. DNA stability 8. Apoptosis induction 9. Immune response 10. Microglial activation 11. Tumor microenvironment 12. Cancer stem cells 13. Targeted therapy 14. Gene expression analysis 15. Biomarker detection 16. Drug sensitivity testing 17. Prognostic factor 18. Genetic therapy 19. Immunotherapy 20. glioblastoma multiforme (GBM)
1. Tocopheryl acetate 2. Prostate cancer prevention 3. Vitamin E supplement 4. Daily dose 5. 400mg dosage 6. Nutritional intake 7. Antioxidant protection 8. Cancer prevention nutrient 9. Enzyme conversion 10. Cancer risk reduction 11. Inverse prostate symptoms 12. Selenium synergy 13. Selenium supplementation 14. Selenium and vitamin E combination 15. Urological health 16. Prostate health benefits 17. Labile form of vitamin E 18. Bioavailability 19. Cancer chemoprevention 20. Clinical trials.
1. Taxation 2. Sugar-sweetened beverages (SSBs) 3. Incidence rate 4. Type II diabetes 5. India 6. Public health policy 7. Sugarcane tax 8. Health impact assessment 9. Sugar consumption 10. Beverage taxes 11. Diabetes prevalence 12. Sugar tax policy 13. Economic intervention 14. Epidemiological study 15. Behavioral change 16. Diabetes prevention 17. Health education 18. Sugar reduction 19. Fiscal policy 20. Health equity.
1. Teaching hospitals vs. non-teaching hospitals 2. Quality of care comparison 3. Patient outcomes study 4.医教学院与非医教学院 5. Medical education vs. patient care 6. Hospital reputation 7. Patient satisfaction surveys 8. Clinical expertise 9. Resident training 10. Patient experience 11. Inpatient services 12. Surgical outcomes research 13. Teaching hospitals vs. private hospitals 14. Non-teaching hospitals: quality benchmarks 15. Continuing education 16. Medical residency programs 17. Patient safety analysis 18. Access to specialists 19. Patient transfer practices 20. Hospital-academic partnerships.
1. Tetraspanin 3 2. Acute Myelogenous Leukemia (AML) 3. Causative factor 4. Development 5. Genetic mutation 6. Hematopoietic stem cells 7. Cancer biology 8. Cell surface proteins 9. Protein function 10. Pathway activation 11. Molecular signaling 12. Genomic alterations 13. Chronic myeloproliferative disorder 14. Prognosis 15. Therapeutic targets 16. Drug discovery 17. Immunotherapy 18. Biomarkers 19. Cellular signaling networks 20. Tumor progression.
1. Deinococcus radiodurans 2. DDRB protein 3. Alternative single-strand binding (SSB) 4. DNA repair 5. Radiation resistance 6. ssDNA binding 7. DNA protection 8. DNA replication 9. DNA repair machinery 10. Heat stability 11. Radix protein family 12. DNA damage response 13. Protein function 14. Bacterial defense mechanism 15. Nucleotide replacement 16. DNA ligase-independent 17. Non-homologous end joining 18. Recombination repair 19. DnaJ chaperone 20. DNA binding affinity
1. PPR (Protein-Protein Interaction) 2. MDA5 (Natural killer group 2, member D5) 3. N-terminal domain 4. Card domain 5. Protein structure 6. Signal transduction 7. Immune response 8. DNA recognition 9. Tumor surveillance 10. Innate immunity 11. Interferon signaling 12. Viral recognition 13. Double-stranded RNA (dsRNA) 14. Type I interferons 15. Host defense mechanism 16. N-terminal extension 17. Membrane-bound protein 18. Immunoproteomics 19. Functional analysis 20. Structural biology
1. PRR (PRR domain) 2. MDA5 (Melanoma differentiation-associated protein 5) 3. Central DNA binding domain 4. DexD (DExH box domain) 5. RNA helix recognition 6. Helical structure 7. Regulatory protein 8. Innate immune response 9. Tumor suppressor 10. Interferon signaling 11. Cytosine-Phosphate-Guanine rich sequences 12. dsRNA recognition 13. Double-stranded RNA helicase activity 14. PRR-MDA5 complex 15. DNA/RNA interaction 16. Antiviral defense 17. Innate immune receptor 18. Gene expression regulation.
1. PRR (Pattern Recognition Receptors) 2. MDA5 (Melanoma-Derived Antiviral Interferons) 3. RNA virus infection 4. Innate immune response 5. dsRNA (double-stranded RNA) 6. IFN-α (interferon alpha) 7. Viral recognition 8. Host defense mechanism 9. Type I interferons 10. Telomerase reverse transcriptase (TERT) 11. Interferon signaling pathway 12. Nuclear translocation 13. Viral sensing 14. Detection of viral nucleic acids 15. Antiviral response 16. Innate immunity sensors 17. RNA helicase activation 18. IFN-inducible genes 19. Host-virus interaction 20. Innate immune surveillance.
1. US healthcare system 2. Cost savings 3. Kidney transplantation 4. Optimized national kidney paired donation (Omnid) 5. Waiting list reduction 6. Patient participation 7. Transplantation efficiency 8. Living donor program 9. altruistic donors 10. Non-transplant alternatives 11. Organ allocation policy 12. Matching algorithms 13. Health outcomes improvement 14. Cost-effective healthcare 15. Public health benefits 16. Quality of life enhancement 17. National Renal Registry 18. Medical research 19. Donor-recipient pairs 20. Health equity.
1. Yap1 2. Tead complex 3. Translocation 4. Nucleus 5. Transcription factors 6. DNA binding proteins 7. Gene transcription 8. Regulatory modulation 9.靶基因 10.基因表达调控 11.DNA结合位点 12.转录激活 13.转录抑制 14.基因沉默 15.基因激活 16.核内互作 17.染色质修饰 18.细胞分化 19.发育生物学 20.基因组稳态
1. DNA data 2. Publicly available 3. Doubling rate 4. Exponential growth 5. Ten-year interval 6. Data storage 7. Genomic information 8. Big data biology 9. Open access genetics 10. DNA sequencing 11. Bioinformatics 12. Genetic databases 13. DNA databases 14. Privacy concerns 15. Genetic information sharing 16. Genome projects 17. Genetic data analysis 18. DNA synthesis 19. Synthetic biology 20. Future predictions in genomics.
1. Arm density 2. Tatad complexes 3. Structural rearrangements 4. Class 1 Tatad complexes 5. Charge zipper mechanism 6. Protein structure 7. DNA binding 8. TAT (Transcriptional Activation Transducer) 9. Amyloid β fibrils 10. Membrane anchoring 11. Intrinsically disordered regions 12. Conformational changes 13. Electrostatic interactions 14. Functional domains 15. Allosteric regulation 16. Multimerization 17. Cysteine-rich motifs 18. Post-translational modifications 19. Protein-protein interactions 20. Structural biology.
1. Safe havens for students 2. Study-friendly environments 3. Academic shelters 4. Community learning centers 5. Public libraries 6. School facilities 7. Safe housing options 8. Education and shelter integration 9. Outreach programs for homeless students 10. College dormitories or housing assistance 11. Study rooms in homeless shelters 12. After-school and homework centers 13. Safe zones for academic pursuits 14. Educational support for homeless individuals 15. Access to stable living + study spaces 16. Dropout prevention initiatives 17. Homelessness prevention programs with study components 18. Community college resources 19. Academic success programs for at-risk populations 20. Student-led study groups for the homeless.
1. Homelessness 2. Safe study places 3. Availability 4. Educational access 5. Academic environment 6. Secure locations 7. Learning facilities 8. Community centers 9. Libraries 10. School buildings 11. Public spaces 12. Homeless shelters 13. Affordable housing 14. Educational resources 15. Dropout prevention 16. Student support services 17. Homelessness reduction strategies 18. Education and shelter correlation 19. Safe havens for learning 20. Inadequate accessibility.
1. Colchicine 2. Benefits 3. Secondary prevention 4. High dose statins 5. Widespread use 6. Cardiovascular disease 7. Arthritis management 8. Anti-inflammatory effects 9. Risk reduction 10. Thromboembolism prevention 11. Atherosclerosis prevention 12. Hypercholesterolemia treatment 13. Lipid-lowering therapy 14. Renal protection 15. Gout management 16. Cardiovascular event prevention 17. Non-pharmacological approach 18. Primary and secondary prevention 19. Patient education 20. Long-term health benefits.
1. Binding orientation 2. ML SA1 activator 3. HTRPML2 4. HTRPML1 5. Different 6. Comparison 7. Molecular recognition 8. Protein-protein interaction 9. Specificity 10. Ligand binding site 11. Structural analysis 12. Active conformation 13. Crystal structure 14. Docking studies 15. Functional implications 16. Allosteric regulation 17. Sequence-activity relationship 18. Structural diversity 19. Functional switch 20. Membrane protein ligand binding.
1. Granuloma 2. Immune cell 3. Center of inflammation 4. Pro-inflammatory response 5. Immunological activation 6. Tissue inflammation 7. Macrophages 8. Microglia 9. Granulomatous inflammation 10. Adaptive immune system 11. Cytokines 12. Interleukins 13. Nuclear factor-kappa B (NF-κB) 14. Toll-like receptors (TLRs) 15. Activation marker 16. Chronic inflammation 17. Chronic granulomatous disease 18. Granuloma formation 19. Innate immunity 20. Immunosuppression.
1. H3K4me3 2. H3K79me2 3. Quiescent hair follicle stem cells 4. Epigenetic marking 5. DNA methylation 6. Histone modification 7. Stem cell biology 8. Hair growth regulation 9. Telomere maintenance 10. Chromatin accessibility 11. Transcriptional repression 12. Cell cycle arrest 13. Stem cell niche 14. Hair follicle development 15. Epigenetic profiling 16. Stem cell quiescence 17. Gene expression control 18. Histone mark co-occurrence 19. Tissue-specific histone modifications 20. Epigenetic memory.
1. Myosin II 2. Isoform switching 3. Polarizable b isoform 4. Homogenous a isoform 5. Hematopoietic differentiation 6. Muscle contraction 7. Cell lineage development 8. Cytoskeleton dynamics 9. Actin-myosin interaction 10. Sarcomere organization 11. Tissue-specific expression 12. Protein isoform modification 13. Gene regulation 14. Cell adhesion and migration 15. Blood cell formation 16. Hematopoietic stem cells 17. Lineage commitment 18. Signal transduction pathways 19. Integrins and cadherins 20. Cell specification during development.
1. Deregulation 2. Prolonged activation 3. Monocytes 4. Inflammatory diseases 5. Immune response 6. Chronic inflammation 7. Macrophages 8. Cytokine overproduction 9. Pro-inflammatory mediators 10. Chronic obstructive pulmonary disease (COPD) 11. Rheumatoid arthritis 12. Lupus 13. Asthma 14. Inflammatory bowel disease (IBD) 15. Autoimmune disorders 16. Chronic fatigue syndrome 17. Cardiovascular disease 18. Allergies 19. Chronic kidney disease 20. Regulatory T cells (Tregs) dysfunction 21. Microenvironmental imbalance 22. Th1/Th17 polarization 23. Exaggerated immune response 24. Macrophage-microglia activation 25. Immunosuppression 26. Pro-inflammatory cytokine storm.
1. Tmem27 2. Extracellular domain 3. Cleavage 4. Human beta cells 5. Cell biology 6. Signal transduction 7. Membrane proteins 8. Proteolytic processing 9. Endocytosis 10. Autophagy 11. Secretory pathway 12. Transmembrane protein 27 13. Beta-cell function 14. Diabetes 15. Pancreatic beta cells 16. Cytokines 17. Hormonal regulation 18.剪切（in Chinese or other languages, if discussing a specific scientific context） 19. Proteinomics 20. Immunology
1. Genomic aberrations 2. Metastases 3. Primary tumor 4. Similarity 5. DNA mutations 6. Copy number variations 7. Chromosomal alterations 8. Cancer genetics 9. Clonal evolution 10. Genetic fingerprinting 11. Heterogeneity 12. Convergent evolution 13. Tumor microenvironment 14. Metastatic spread 15. Cancer metastasis 16. Spreading of genetic changes 17. Gene expression profiles 18. Epigenetic modifications 19. Cancer stem cells 20. Genomic concordance 21. Prognostic indicators 22. Therapeutic targets 23. Precision medicine 24. Molecular diagnostics 25. Cancer recurrence
1. Locus 2. Colorectal 3. Carcinoma 4. Genetic predisposition 5. DNA mutation 6. Epigenetics 7. Genomic location 8. Cancer susceptibility 9. BRCA1/2 genes 10. Microsatellite instability (MSI) 11. Lynch syndrome 12. CpG islands 13. Non-polypous polyposis 14. serrated adenomas 15. Familial adenomatous polyposis (FAP) 16. Colorectal adenocarcinoma 17. Pathway analysis 18. Environmental factors 19. Biomarkers 20. Prevention and screening.
1. Tet protein 2. Loss of function 3. Biological consequences 4. Myeloid cancers 5. Genetic mutation 6. Hematopoiesis 7. Immune system dysregulation 8. T cell development 9. Cancer risk 10. Pro-inflammatory environment 11. Iron metabolism 12. DNA stability 13. Epigenetic changes 14. Chronic inflammation 15. Genetic disorders 16. Cancer stem cells 17. TET enzymes 18. Myeloid leukemia 19. Myelodysplastic syndrome 20. Cytokine imbalance.
1. Minor G allele 2. Foxo3 gene 3. Crohn's disease 4. Severe symptoms 5. Genetic association 6. Inflammation 7. Immune response 8. Genetic risk factor 9. CD (Crohn's disease) 10. Genetic variation 11. Gene polymorphism 12. FOXP3 protein 13. Inflammatory bowel disease 14. Pathogenesis 15. Genetic testing 16. Disease severity 17. Genetic susceptibility 18. Genetic epidemiology 19. Environmental interactions 20. Therapeutic implications.
1. Myocardial lineage 2. Cardiac progenitors 3. Mesodermal origin 4. Developmental biology 5. Heart tissue 6. Cardiovascular development 7. Heart muscle cells 8. Endocardial, epicardial, and myocardial derivatives 9. Mesoderm 10. Tissue differentiation 11. Nodal signaling 12. Wnt/β-catenin pathway 13. Sonic hedgehog (Shh) 14. BMP (bone morphogenetic proteins) 15. Notch signaling 16.cardiac specification 17. Mesodermal condensation 18. Heart field formation 19. Hematopoietic to mesenchymal transition (HMT) 20. Cardiac myogenesis.
1. One-Child Policy 2. Population Growth Control 3. Success 4. Lowering Birth Rates 5. Family Planning 6. Birth Limitation 7. Population Management 8. Economic Development 9. Demographic Transition 10. Social Stability 11. Population Density 12. Birth Control Programs 13. National Policy 14. Population Decline 15. Chinese Family Planning 16. Unprecedented Effectiveness 17. Statistical Reduction 18. Population Aging 19. Birth Rate Reduction Strategy 20. Long-term Goals
1. Breast cancer 2. Tamoxifen metabolism 3. Genetic makeup 4. Treatment outcome 5. Drug response 6. Pharmacogenetics 7. Cancer metabolism 8. Cancer genomics 9. Drug efficacy 10. Personalized medicine 11. CYP2D6 metabolism 12. Hormone receptor status 13. Breast cancer drug resistance 14. Genetic predisposition 15. Adverse drug reactions 16. Pharmacokinetics 17. Breast cancer genetics 18. Tamoxifen toxicity 19. Cancer genetic testing 20. Chemoresistance.
1. Cas9 editing 2. DNA repair mechanisms 3. Double-strand break (DSB) 4. Homologous recombination (HR) 5. Non-homologous end joining (NHEJ) 6. Error-prone repair 7. Mutagenesis 8. Base insertion/deletion (indels) 9. Nucleotide mismatch repair (NMR) 10. DNA polymerase精度 11. DNA ligase function 12. Repair fidelity 13. HR efficiency 14. NHEJ accuracy issues 15. Cas9 off-target effects 16. Genetic instability 17. DNA sequencing analysis 18. Gene therapy 19. Genetic engineering 20. Precision gene editing challenges
1. Breast cancer risk 2. Parous women 3. Placental weight 4. Pregnancies 5. Association 6. Increased risk 7. Premenopausal breast cancer 8. Gynecological health 9. Reproductive history 10. Maternal factors 11. Pregnancy complications 12. Fetal development 13. Obstetrics 14. Hormonal changes 15. Glandular transformation 16. Breast tissue density 17. Maternal age 18. Breastfeeding 19. Risk factors 20. Cancer epidemiology.
1. Male prisoners 2. Self-harm 3. Risk ratio 4. Comparative analysis 5. Gender disparity 6. Incarceration 7. Suicide 8. Female prisoners 9. Statistical data 10. Correctional facilities 11. Mental health 12. Risk factors 13. Detention centers 14. Behavioral health 15. Self-injury 16. Male suicide 17. Prisoner well-being 18. Prevalence 19. Risk assessment 20. Male correctional population
1. Amyloidosis 2. Cardiac involvement 3. Severity 4. Late gadolinium enhancement (LGE) 5. Magnetic resonance imaging (MRI) 6. Transmurality 7. Myocardial infiltration 8. Cardiac muscle involvement 9. Amyloid protein deposition 10. Altered tissue integrity 11. Infarction grading 12. Scar formation 13. Amyloid burden 14. Prognostic indicator 15. Cardiac function assessment 16. Cardiac MRI 17. Amyloidosis types (AL, AA, etc.) 18. Diagnostics 19. Treatment response 20. Progression monitoring
1. Single flash 2. Evoked erg B wave 3. Bipolar cells 4. Visual processing 5. Retinal activity 6. Optic nerve response 7. Ganglion cell firings 8. Phototransduction 9. Visual stimulus 10. Light detection 11. Electrophysiology 12. Eye physiology 13. Retinal physiology 14. Action potential 15. Electrical signal transmission 16. Inner retina 17. Electromagnetic induction 18. Visual cortex interaction 19. Functional connectivity 20. Visual pathway analysis.
1. Sliding activity 2. Kinesin 8 protein (Kip3) 3. Bipolar spindle assembly 4. Microtubule dynamics 5. Motor protein function 6. Cytokinesis 7. Mitotic checkpoint 8. Spindle pole formation 9. Kinesin-based motility 10. Kinetic proofreading 11. Plus-end tracking 12. Cdc14/Cdk1 regulation 13. Anaphase-promoting complex (APC) 14. Chromosome segregation 15. Centrosome separation 16. Cilia and flagella assembly 17. Cell division 18. Miro/Kinesin-8 family 19. Polo-like kinase (PLK) interaction 20. Mitotic checkpoint kinases (MCKs) activation.
1. T6SS (Type VI Secretion System) 2. Inner tube or pilus 3. Toxic effectors 4. Vi secretion system 5. Escherichia coli (E. coli) 6. Antibacterial defense 7. Effector proteins 8. Toxins produced by E. coli 9. Flagellar T6SS 10. Type VI secretion mechanism 11. Secretory pathway in bacteria 12. Adhesion and invasion 13. Pili-mediated delivery 14. Competitive exclusion 15. Genetic determinants 16. Quorum sensing 17. Biofilm formation 18. Stress response 19. Extracellular vesicles 20. Antimicrobial resistance.
1. Cancer treatment 2. Co-ir blockades 3. Autoimmune disorders 4. Adverse events 5. Patient safety 6. Immune-oncology drugs 7. Immunosuppressive therapy 8. Chronic obstructive pulmonary disease (COPD) targeted therapies 9. Anti-PD-1/PD-L1 inhibitors 10. Ipilimumab 11. Nivolumab 12. Pembrolizumab 13. Checkpoint inhibitors 14. Tumor-infiltrating lymphocytes (TILs) 15. Clinical trials 16. Case studies 17. Long-term follow-up 18. Drug tolerance 19. Cancer immunotherapy 20. Clinical efficacy
1. Cancer treatment 2. Co-ir blockades 3. Adverse autoimmune reactions 4. Immune checkpoint inhibitors (ICIs) 5. Immunosuppressive therapy 6. Chronic inflammation 7. Oncoimmunology 8. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors 9. Programmed death-1 (PD-1) inhibitors 10. Proliferative autoimmune syndrome 11. Hypersensitivity reactions 12. Autoimmune thyroiditis 13. Colitis 14. Renal dysfunction 15. Graft-versus-host disease (GVHD) 16. Infusion-related reactions 17. Clinical monitoring 18. Risk stratification 19. Patient education 20. Prevention strategies.
1. Ureabiefgh gene cluster 2. Urease maturation proteins 3. ured 4. Ureh 5. Ureic acid 6. Ureification 7. Uregenesis 8. Urease biosynthesis 9. Enzymatic activity 10. Metabolic process 11. Nitrogen metabolism 12. Ammonification 13. Bacterial ureolysis 14. Soil biology 15. Plant rhizosphere 16. Gene regulation 17. Protein expression 18. Genetic engineering 19. Functional analysis 20. Bioinformatics
1. Ureabiegfh gene cluster 2. Nickel II ion induction 3. Gene regulation 4. Metal cation response 5. Bacterial metabolism 6. Metal toxicity tolerance 7. Nickel-responsive genes 8. Metallothioneins 9. Operon expression 10. Environmental sensing 11. Biochemical pathway 12. Adaptive response 13. Nickel-induced expression 14. Transcription factors 15. DNA binding site 16. Metal-responsive element (MRE) 17. Signal transduction 18. Genetic engineering 19. Bioremediation 20. Industrial biotechnology
1. Dapsone 2. Therapeutic use 3. Pyoderma gangrenosus 4. Anecdotal evidence 5. Clinical trials 6. Case reports 7. Treatment efficacy 8. Skin infection 9. Antibacterial therapy 10. Infection management 11. Patient anecdotes 12. Off-label use 13. Drug efficacy in pyogangrene 14. Post-exposure prophylaxis 15. Topical dapsone 16. Systemic dapsone 17. Wound healing 18. Prognosis improvement 19. Safety concerns 20. Evidence-based medicine (EBM) review
1. Hip fractures 2. Statin use 3. Inverse relationship 4. Correlation 5. Risk reduction 6. Drug interactions 7. Bone health 8. Cardiovascular medication 9. Statins and osteoporosis 10. Fracture prevention 11. Statin therapy 12. Metabolism drugs 13. Hip protectors 14. Age-related decline 15. Secondary prevention 16. Cardiovascular disease 17. Potential harm 18. Long-term effects 19. Epidemiology 20. Medication adjustment
1. HNF4A mutations 2. Diabetes risk 3. Genetic association 4. Non-existent link 5. Phenotype-genotype analysis 6. Renal dysplasia 7. Pancreatic dysfunction 8. Type 1 and 2 diabetes 9. Hormonal regulation 10. Kidney disease 11. Cystic fibrosis-related diabetes 12. Diabetes susceptibility 13. Gene polymorphisms 14. Genetic testing 15. Population-based studies 16. Functional studies 17. mendelian inheritance 18. Environmental影响 19. HNF4A gene 20. Clinical implications.
1. Thigh length 2. Graduated compression stockings (GCS) 3. Deep vein thrombosis (DVT) 4. Hospitalized patients 5. Acute stroke 6. Immobility 7. Venous compression therapy 8. DVT prevention 9. Stroke recovery 10. Post-stroke care 11. Risk reduction 12. Clinical trial 13. Prophylaxis 14. Complications in stroke patients 15. Patient mobility assessment 16. Sequential compression devices 17. Stroke rehabilitation 18. Vascular health 19. Inpatient management 20. Hemodynamic improvement
1. Tirasemtiv 2. Fast twitch muscle 3. No effect 4. Muscular performance 5. Exercise physiology 6. Neuromuscular blocking agent 7. Twitch contraction 8. Fatigue resistance 9. Contractile strength 10. Myotonia 11. Creatine kinase 12. High-intensity exercise 13. ATPase activity 14. Skeletal muscle fibers 15. Twitch fiber type 16. Sarcomeric properties 17. TIR3 (tirasemtiv receptor) 18. Non-dystrophic myopathy 19. Drug sensitivity study 20. Therapeutic nullification
1. Transferred 2. UCB T cells (Unselected Cancer Cell Derived T-cells) 3. Acquire 4. Memory-like phenotype 5. Recipients 6. Immune response 7. T cell differentiation 8. Central memory cells 9. Effector memory cells 10. Epitope recognition 11. Secondary immune response 12. Chronic infection 13. T cell homeostasis 14. Antigen-specificity 15. Immune tolerance 16. Cellular immunology 17. Transplant rejection 18. Stem cell transplantation 19. Regulatory T cells 20. Immunomemory enhancement.
1. Transplantation 2. Human glial cells 3. Differentiation 4. Host animal 5. Neural regeneration 6. Neural tissue engineering 7. Immune acceptance 8. Cellular integration 9. Neuroprogenitor cells 10. Neuronal differentiation 11. Schwann cells 12. Oligodendrocytes 13. Astrocytes 14. Chondrocyte-like differentiation 15. Tissue integration 16. In vivo study 17. Ex vivo expansion 18. Neural repair 19. Functional recovery 20. Induced pluripotent stem cells (iPSCs)
1. Transplantation 2. Human glial progenitor cells 3. Neural network 4. Host animal neurons 5. Integration 6. Cellular rejection 7. Compatibility 8. Differentiation 9. Neuronal connectivity 10. Neuroregeneration 11. Functional integration 12. Paracrine signaling 13. Immune response 14. Scaffold-assisted growth 15. Cell survival 16. Graft versus host disease 17. Neuroinflammation 18. Neural tissue engineering 19. Neural progenitor cell therapy 20. Induction of neurogenesis.
1. Tumor Necrosis Factor Alpha (TNF-α) 2. Interleukin-1 (IL-1) 3. Pro-inflammatory cytokines 4. Inhibition 5. Interleukin-6 (IL-6) 6. Interleukin-10 (IL-10) 7. Immune response 8. Chronic inflammation 9. Cytokine signaling 10. Chronic disease 11. Autoimmunity 12. Inflammation regulation 13. Adaptive immune response 14. Pathogenesis 15. Anti-inflammatory drugs 16. Th1/Th2 balance 17. Nuclear factor-kappa B (NF-κB) 18. Cytokine cascade 19. Chronic obstructive pulmonary disease (COPD) 20. Rheumatoid arthritis (RA)
1. UCB (Unrelated Donor) T cells 2. Transplantation 3. T cell diversity 4. T Cell Receptor (TCR) 5. HLA compatibility 6. Immune rejection 7. Allogenic transplant 8. Regulatory T cells (Tregs) 9. Antigen specificity 10. Clonal expansion 11. Chimerism 12. Post-transplant immune response 13. Donor-versus-host response 14. TCR repertoire analysis 15. T-cell homeostasis 16. Transplant tolerance 17. Cellular memory 18. Gene editing (e.g., CAR-T cells) 19. Transplantation-induced immune modulation 20. T cell engraftment and persistence.
1. UCB (University of California, Berkeley) 2. T cells 3. T cell receptor (TCR) diversity 4. Transplantation 5. Allogenic transplant 6. Immune rejection 7. Regulatory T cells (Tregs) 8. Donor-specific tolerance 9. Cellular immunosuppression 10. Allogenic immune response 11. HLA compatibility 12. graft-versus-host disease (GVHD) 13. T cell engraftment 14. Chimerism 15. Donor HLA-reactivity 16. T cell exhaustion 17. TCR repertoire modification 18. Immune reconstitution 19. Post-transplant immunosuppression 20. T cell homeostasis.
1. Ubiquitin ligase 2. Ubc13 3. K63 linked polyubiquitin 4. PCNA (histones H2A, H2B, and H2C) 5. K164 modification 6. Ubiquitination 7. Proteasome degradation 8. DNA damage response 9. DNA repair 10. chromatin modification 11. histone ubiquitination 12. C-terminal tail of PCNA 13. Ubiquitin-protein ligase activity 14. Ubiquitin E3 enzyme 15. Cellular signaling 16. DNA replication checkpoint 17. DNA-PKcs-dependent pathway 18. DNA damage tolerance 19. Translational control 20. Protein stability.
1. Ultrasound guidance 2. Traumatic procedures 3. Needle insertion 4. Enhanced accuracy 5. Precision insertion 6. Safe procedure 7. Minimally invasive 8. Reduced complications 9. Patient safety 10. Anesthesia administration 11. Transverse ultrasound 12. Real-time imaging 13. Sonographic localization 14. Point-of-care ultrasound 15. Training and education 16. Improved patient outcomes 17. Puncture success rate 18. Needle tract assessment 19. Neurological procedures 20. Orthopedic interventions 21. Interventional radiology 22. Vascular access 23. Pain management 24. Emergency situations 25. Ultrasound-guided nerve blocks.
1. P53 pathway upregulation 2. Cancer resistance mechanisms 3. Molecular events involved 4. Senescent cells 5. Cellular aging 6. DNA damage response 7. Apoptosis inhibition 8. Tumor suppressor gene 9. Oncogene activation 10. p53 protein function 11. Cell cycle arrest 12. DNA repair genes 13. Senescence-inducing stimuli 14. Senescence marker proteins (SMPs) 15. Telomere shortening 16. Senescence-associated beta-galactosidase (SA-beta-Gal) 17. Senescence-inducing transcription factors (SIRTs) 18. Epigenetic modifications 19. Autophagy deregulation 20. Metabolic changes 21. Aging-related diseases 22. Senescence-associated secretory phenotype (SASP) 23. Stem cell exhaustion 24. Cancers with senescence escape 25. Pro-inflammatory response 26. Senolytics (anti-senescent drugs)
1. Upregulation 2. Mosgctl1 3. Induction 4. West Nile Virus 5. Infection 6. Gene expression 7. Regulatory mechanism 8. Transcriptional activation 9. Viral infection-induced response 10. Signal transduction 11. Mos (Mitogen-activated protein kinase) 12. Host-virus interaction 13. Immune response 14. Cellular defense 15. Pathway activation 16. Signaling molecule 17. Gene ontology 18. Functional analysis 19. Biomarker discovery 20. Virus-host coevolution.
1. Varenicline 2. Monotherapy 3. 12-week treatment 4. Comparison 5. Combination therapy 6. Nicotine replacement therapy (NRT) 7. Bupropion 8. Efficacy 9. Quit smoking 10. Drug efficacy study 11. Long-term effectiveness 12. Chirality effect 13. Nicotine patch 14. Nicotine gum 15. Inhaler nicotine 16. patches and gum co-administration 17. Bupropion SR 18. Varenicline alone vs. combined 19. Smoking cessation 20. Randomized controlled trials (RCTs)
1. Venules 2. Lumen diameter 3. Arterioles 4. Blood flow 5. Capillaries 6. Blood vessel size 7. Blood pressure regulation 8. Exchange of nutrients and gases 9. Circulatory system 10. Blood vessel structure 11. Respiratory and metabolic function 12. Venous return 13. Microcirculation 14. Blood vessel caliber 15. Diameter comparison 16. Capillary beds 17. Blood vessel anatomy 18. Blood volume distribution 19. Blood perfusion 20. Oxygen transport.
1. Venules 2. Smooth layer 3. Thinner 4. Absent 5. Arterioles 6. Blood vessels 7. Capillaries 8. Microcirculation 9. Wall thickness 10. Blood flow regulation 11. Pericytes 12. Endothelial cells 13. Venous system 14. Arterial system 15. Blood vessel classification 16. Hypertrophy 17. Atrophy 18. Blood vessel diameter 19. Intima 20. Media 21. Adventitia.
1. Vitamin D deficiency 2. Fetal development 3. Pregnancy outcomes 4. Neonatal health 5. Postpartum complications 6. Birth weight 7. Preterm birth 8. Spontaneous abortion 9. Maternal bone health 10. Immune system function 11. Gestational diabetes 12. Intrauterine growth restriction 13. Neural tube defects 14. Calcium absorption 15. Renal health 16. Dental health 17. Postnatal depression 18. Immune system response 19. Postpartum recovery 20. Maternal osteoporosis
1. Vitamin D deficiency 2. Birth weight 3. Unrelated 4. Health connection 5. Neonatal development 6. Nutrition 7.孕妇健康 8.婴儿体重 9. Iodine supplementation 10. Bone health 11. Immune system 12. Rickets 13. Cesarean section 14. Breastfeeding 15.太阳暴露 16. Genetic predisposition 17. Calcium intake 18.孕妇饮食 19. Medical research 20. Maternal supplementations
1. Women 2. Birth weight 3. Higher birth weight 4. Breast cancer 5. Later in life 6. Increased risk 7. Statistical association 8. Development 9. Gender-specific health issue 10. Maternal factors 11. Neonatal health 12. Breast tissue 13. Genetic predisposition 14. Environmental factors 15. Life course 16. Screening and detection 17. Prevention strategies 18. Early detection 19. Risk factors 20. Breast oncology
1. APKcz 2. Tumour enhancement 3. Glutamine metabolism 4. Cellular proliferation 5. Metabolic dysregulation 6. Immune response 7. Tumor growth promotion 8. Apoptosis inhibition 9. Enzymatic activity 10. Cancer signaling pathways 11. Metabolic stress 12. glutaminase regulation 13. Tumor microenvironment 14. Inosine monophosphate (IMP) accumulation 15. Metabolic reprogramming 16. Anti-cancer drugs 17. Preclinical research 18. Drug targets 19. Tumor biology 20. Apoptosis resistance.
1. CSMAC (Cell-Surface Macromolecular Complex) 2. Ligand signaling 3. Weak ligand binding 4. Signal transduction 5. Enhance receptor activity 6. Cell membrane interaction 7. Signal strength improvement 8. Ligand-receptor affinity 9. Protein-protein complex formation 10. Signal amplification 11. Intracellular communication 12. Cell surface receptor modification 13. Ligand-induced response 14. CSMAC function 15. Signal specificity 16. Signal translocation 17. Signal decoding 18. Signal regulation 19. Ligand-receptor cooperativity 20. CSMAC-based therapies.
1. mtORC2 (Mitochondrial Regulatory Complex 2) 2. Intracellular cysteine levels 3. Cysteine transport 4. XCT (xanthine oxidase/cysteine dioxygenase) 5. Inhibition mechanism 6. Metabolic regulation 7. Redox homeostasis 8. Protein synthesis 9. Mitochondrial function 10. Cysteine metabolism 11. Xenobiotic detoxification 12. Oxidative stress response 13. Phosphorylation events 14. Signaling pathways 15. Cellular energetics 16. Transcription factor activation 17. Cysteine transporters 18. Nutrient sensing 19. Cancer biology 20. Drug targets
1. P16ink4a accumulation 2. Abnormal wound response 3. Microinvasive step 4. Advanced oral potentially malignant lesions (OPMLs) 5. Cancerous precursor 6. Oral cavity lesions 7. Tumor progression 8. Genetic alterations 9. Wound healing dysregulation 10. Epigenetic changes 11. Oncogenic signaling 12. Pathological wound healing 13. OPML staging 14. Risk assessment 15. Early detection 16. Biomarkers 17. Clinicopathological correlation 18. Immunohistochemistry 19. Genomic profiling 20. Targeted therapies.
